

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) Publication number:

0 389 037 B1

(12)

EUROPEAN PATENT SPECIFICATION

- (45) Date of publication of patent specification: 20.09.95 (51) Int. Cl.⁶: **C07D 405/12, C07D 405/14, C07D 409/14, C07D 307/84, C07D 311/58, C07D 313/08, C07D 317/68, C07D 319/16, C07D 321/08, A61K 31/445**
- (21) Application number: 90200589.1
- (22) Date of filing: 13.03.90

- (54) **N-(3-hydroxy-4-piperidiny)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)carboxamide derivatives.**

- (30) Priority: 22.03.89 US 326941
- (43) Date of publication of application: 26.09.90 Bulletin 90/39
- (45) Publication of the grant of the patent: 20.09.95 Bulletin 95/38
- (84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE
- (56) References cited:
- | | |
|-----------------|-----------------|
| EP-A- 0 069 482 | EP-A- 0 124 783 |
| EP-A- 0 147 044 | EP-A- 0 299 566 |
| EP-A- 0 307 172 | DE-A- 3 702 005 |
| US-A- 4 772 459 | |

- (73) Proprietor: **JANSSEN PHARMACEUTICA N.V.**
Turnhoutseweg 30
B-2340 Beerse (BE)
- (72) Inventor: **Van Daele, Georges Henri Paul**
Kongostraat 156
B-2300 Turnhout (BE)
Inventor: **Van den Keybus, Frans Maria Alfons**
Kortestraat 16
B-2190 Essen (BE)

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid (Art. 99(1) European patent convention).

EP 0 389 037 B1

Description

Background of the invention

A number of substituted (3-hydroxy-4-piperidiny)benzamide derivatives have been described as stimulators of the motility of the gastrointestinal system in EP-A-0,076,530, EP-A-0,299,566 and EP-A-0,309,043.


In EP-A-0,307,172; EP-A-0,124,783; DE-3,702,005; EP-A-0,147,044; EP-A-0,234,872 and US-4,772,459 there are described benzofuran, benzopyran or benzoxepin carboxamide derivatives being substituted on the nitrogen with an alkylamino group or with a mono- or bicyclic hetero ring optionally through an alkyl chain. These compounds are taught to be anti-emetic, anti-psychotic or neuroleptic agents.

In the EP-A-0,068,700; BE-0,890,962; FR-2,396,757 there are described dihydrobenzodioxin carboxamide derivatives being substituted on the nitrogen with a mono- or bicyclic hetero ring. These compounds are claimed to be useful in the treatment of disorders of the central nervous system and as anti-emetic agents.

The N-(3-hydroxy-4-piperidiny)(dihydrobenzofuran, dihydro-2H-benzopyran or dihydrobenzodioxin)-carboxamide derivatives of the present invention differ therefrom structurally and pharmacologically by their favourable gastrointestinal motility stimulating properties. In particular the present compounds show unexpected motility enhancing effects on the colon.

Description of the invention

The present invention is concerned with novel benzamide derivatives having the formula



the N-oxide forms, the therapeutically active non-toxic addition salts and the stereochemically isomeric forms thereof, wherein :

A is a radical of formula

-CH₂-CH₂- (a-1),

-CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5),

or

-CH₂-CH₂-CH₂-O- (a-6),

wherein one or two hydrogen atoms in said radicals (a-1) to (a-6) may be replaced by a C₁₋₆ alkyl radical;

R¹ is hydrogen, halo;

R² is amino, mono or di(C₁₋₆ alkyl)amino, arylC₁₋₆ alkylamino or C₁₋₆ alkylcarbonylamino;

R³ and R⁴ are each independently hydrogen or C₁₋₆ alkyl;

L is C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, C₃₋₆ alkenyl optionally substituted with aryl, or L is a radical of formula

-Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

5

-Alk-Y-C(=O)-R⁸ (b-3),

or

10

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4),

wherein each Alk is C₁₋₆ alkanediyl; and

R⁵ is hydrogen, cyano, C₁₋₆ alkylsulfonylamino, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, aryl, di(aryl)methyl or Het;

15

R⁶ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or Het;

X is O, S, SO₂ or NR⁷; said R⁷ being hydrogen, C₁₋₆ alkyl or aryl;

R⁸ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, arylC₁₋₆ alkyl, di(aryl)methyl or C₁₋₆ alkyloxy;

Y is NR⁹ or a direct bond; said R⁹ being hydrogen, C₁₋₆ alkyl or aryl;

20

R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or arylC₁₋₆ alkyl, or R¹⁰ and R¹¹ combined with the nitrogen atom bearing R¹⁰ and R¹¹ may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C₁₋₆ alkyl, amino or mono or di(C₁₋₆ alkyl)amino, or said R¹⁰ and R¹¹ combined with the nitrogen bearing R¹⁰ and R¹¹ may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C₁₋₆ alkyl;

25

each aryl being unsubstituted phenyl or phenyl substituted with 1,2 or 3 substituents each independently selected from halo, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkyloxy, aminosulfonyl, C₁₋₆ alkylcarbonyl, nitro, trifluoromethyl, amino or aminocarbonyl; and

30

each Het being a five- or six-membered heterocyclic ring containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that no more than 2 oxygen and/or sulfur atoms are present, said five- or six-membered ring being optionally condensed with a five- or six-membered carboxylic or heterocyclic ring also containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that the latter ring does not contain more than 2 oxygen and/or sulfur atoms and that the total number of heteroatoms in the bicyclic ring system is less than 6; when Het is a monocyclic ring system it may optionally be substituted with up to 4 substituents; when Het is a bicyclic ringsystem it may optionally be substituted with up to 6 substituents; said substituents being selected from the group consisting of halo, hydroxy, cyano, trifluoromethyl, C₁₋₆ alkyl, arylC₁₋₆ alkyl, aryl, C₁₋₆ alkyloxy, C₁₋₆ alkyloxyC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkylthio, mercapto, nitro, amino, mono and di(C₁₋₆ alkyl)amino, arylC₁₋₆ alkylamino, aminocarbonyl, mono and di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyloxycarbonyl, arylC₁₋₆ alkyloxycarbonyl, a bivalent radical = O and = S; provided that when R⁶ is Het, Het is connected to X on a carbon atom.

35

40

As used in the foregoing definitions "halo" is generic to fluoro, chloro, bromo and iodo; "C₁₋₆ alkyl" defines straight and branch chained saturated hydrocarbon radicals having from 1 to 6 carbon atoms such as, for example, methyl, ethyl, propyl, butyl, hexyl, 1-methylethyl, 2-methylpropyl and the like; "C₃₋₆ cycloalkyl" is generic to cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl; "C₅₋₆ cycloalkanonyl" is generic to cyclopentanonyl and cyclohexanonyl; "C₃₋₆ alkenyl" defines straight and branch chained hydrocarbon radicals containing one double bond and having from 3 to 6 carbon atoms such as, for example, 2-propenyl, 3-butenyl, 2-butenyl, 2-pentenyl, 3-pentenyl, 3-methyl-2-butenyl and the like; and when a C₃₋₆ alkenyl is substituted on a heteroatom, then the carbon atom of said C₃₋₆ alkenyl connected to said heteroatom preferably is saturated; "C₁₋₆ alkanediyl" defines bivalent straight or branch chained hydrocarbon radicals containing from 1 to 6 carbon atoms such as, for example, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl, 1,5-pentanediyl, 1,6-hexanediyl and the branched isomers thereof.

45

50

The therapeutically active non-toxic addition salt forms can conveniently be obtained by treating the base form with such appropriate acids as inorganic acids, for example, hydrohalic acids, e.g. hydrochloric, hydrobromic and the like, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted by treatment with alkali into the free base form.

55

The compounds of formula (I) containing acidic protons may also be converted into their therapeutically active non-toxic metal or amine salt forms by treatment with appropriate organic or inorganic bases.

The term addition salt also comprises the hydrates and solvent addition forms which the compounds of formula (I) are able to form. Examples of such forms are e.g. hydrates, alcoholates and the like.

5 The N-oxides of the compounds of formula (I) are meant to comprise those compounds of formula (I) wherein one or several nitrogen atoms are oxidized to the N-oxide form, in particularly those N-oxides wherein the piperidine-nitrogen is N-oxidized.


The compounds of formula (I) have at least two asymmetric carbon atoms in their structure, namely those located in the 3- and the 4-position of the piperidine nucleus. It is evident that the stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of the invention. Furthermore the compounds of the present invention may form cis/trans isomers, more particularly, the substituents in said 3- and 4-positions of the piperidine nucleus may have either a trans or cis-configuration; and such cis/trans isomers too are intended to be within the scope of the present invention.

In the compounds of formula (I) wherein R^5 and R^6 is Het, said Het may be partly or completely saturated, or unsaturated. The compounds of formula (I) wherein Het is partly saturated or unsaturated and is substituted with hydroxy, mercapto or amino, may also exist in their tautomeric forms. Such forms although not explicitly indicated hereinabove, are intended to be included within the scope of the invention. In particular, Het may be :

- i) an optionally substituted five- or six-membered heterocyclic ring containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that no more than 2 oxygen and/or sulfur atoms are present; or
 - ii) an optionally substituted five- or six-membered heterocyclic ring containing 1,2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen, being fused with an optionally substituted five- or six-membered ring through 2 carbon atoms or 1 carbon and 1 nitrogen atom, containing in the remainder of the fused ring only carbon atoms; or
 - iii) an optionally substituted five- or six-membered heterocyclic ring containing 1,2 or 3 heteroatoms selected from oxygen, sulfur and nitrogen, being fused with an optionally substituted five- or six-membered heterocyclic ring through 2 carbon atoms or 1 carbon and 1 nitrogen atom, containing in the remainder of the fused ring 1 or 2 heteroatoms selected from oxygen, sulfur and nitrogen;
- wherein Het being a monocyclic ring system may be optionally substituted with up to 4 substituents; and wherein Het being a bicyclic ring system may be optionally substituted with up to 6 substituents, said substituents being the same as defined hereinabove.

A more particular subgroup of Het comprises cyclic ether or thioether ring systems containing one or two oxygen and/or sulfur atoms, provided that when two oxygen and/or sulfur atoms are present, they are in non-adjacent positions in the ring. Said cyclic ether or thioether ring systems are optionally condensed with a five- or six-membered carbocyclic ring. These cyclic ether or thioether ring systems may also be substituted with one or more C_{1-6} alkyl, C_{1-6} alkyloxy, C_{1-6} alkyloxy C_{1-6} alkyl or hydroxy C_{1-6} alkyl substituents. This subgroup of Het radicals will be represented by the symbol Het¹.

Typical cyclic ethers and thioethers which are covered by R^5 being Het in the compounds of the present invention can be represented by the following formulae :



wherein each X^1 and X^2 each independently are O or S; m is 1 or 2; each R^{12} is hydrogen, C_{1-4} alkyl, C_{1-4} alkyloxy C_{1-4} alkyl or hydroxy C_{1-4} alkyl and R^{13} is hydrogen, halo or C_{1-4} alkyl.


Further particular cyclic ethers are selected from the group consisting of 1,3-dioxolanyl optionally substituted with C_{1-4} alkyl, 1,3-dioxanyl optionally substituted with C_{1-4} alkyl, tetrahydrofuranyl optionally substituted with C_{1-4} alkyl, tetrahydropyranyl optionally substituted with C_{1-4} alkyl, 2,3-dihydro-1,4-benzodioxinyl, 2,3-dihydrobenzofuran and 3,4-dihydro-1(2H)-benzopyranyl, with tetrahydrofuranyl being preferred.

Another more particular subgroup of Het comprises heterocyclic ring systems which are selected from the group consisting of pyridinyl which is optionally substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkyloxy, aminocarbonyl, mono and di(C_{1-6} alkyl)aminocarbonyl, amino, mono and di(C_{1-6} alkyl)amino and C_{1-6} alkyloxycarbonyl; pyrimidinyl which is optionally substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino and mono and di(C_{1-6} alkyl)amino; pyridazinyl which is optionally substituted with C_{1-6} alkyl or halo; pyrazinyl which is optionally substituted with one or two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- and di(C_{1-6} alkyl)amino and C_{1-6} alkyloxycarbonyl; pyrrolyl which is optionally substituted with C_{1-6} alkyl; pyrazolyl which is optionally substituted with C_{1-6} alkyl; imidazolyl which is optionally substituted with C_{1-6} alkyl; triazolyl which is optionally substituted with C_{1-6} alkyl; quinolinyl optionally substituted with up to two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono and di(C_{1-6} alkyl)amino and trifluoromethyl; isoquinolinyl optionally substituted with up to two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono and di(C_{1-6} alkyl)amino and trifluoromethyl; quinoxalinyl optionally substituted with up to two substituents each independently selected from C_{1-6} alkyl, hydroxy, halo, cyano and C_{1-6} alkyloxy; quinoxalinyl optionally substituted with C_{1-6} alkyl; benzimidazolyl optionally substituted with C_{1-6} alkyl; indolyl optionally substituted with up to two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- and di(C_{1-6} alkyl)amino and trifluoromethyl; 5,6,7,8-tetrahydroquinolinyl optionally substituted with up to two substituents each independently selected from C_{1-6} alkyl, hydroxy, halo, cyano and C_{1-6} alkyloxy; thiazolyl optionally substituted with C_{1-6} alkyl; oxazolyl optionally substituted with C_{1-6} alkyl; benzoxazolyl optionally substituted with C_{1-6} alkyl; benzothiazolyl optionally substituted with C_{1-6} alkyl. This subgroup of Het radicals will be represented by the symbol Het².

Further particular heterocyclic ring systems within this subgroup are ring systems wherein Het is an optionally substituted six-membered aromatic ring such as, for example, pyridinyl optionally substituted with up to two substituents selected from C_{1-4} alkyl, cyano, halo and trifluoromethyl; pyrimidinyl, optionally substituted with up to two substituents selected from hydroxy, amino, mono and di(C_{1-4} alkyl)amino and C_{1-4} alkyl; pyrazinyl optionally substituted with cyano, halo, C_{1-4} alkyloxycarbonyl and C_{1-4} alkyl; and pyridazinyl optionally substituted with halo.

Another more particular subgroup of Het comprises optionally substituted five- or six-membered cyclic amides containing one, two or three nitrogen atoms, said five or six-membered heterocyclic ring being optionally condensed with a five- or six-membered carbocyclic or heterocyclic ring containing one or two nitrogen atoms or one sulfur or oxygen atom. This subgroup of Het will be represented hereinafter by the symbol Het³.

Typical monocyclic amides covered by R⁵ and R⁶ being Het in the compounds of the present invention; can be represented by the following formulae:



wherein

X³ is O or S;

R¹⁴ is hydrogen, C_{1-6} alkyl or aryl(C_{1-6} alkyl);


R¹⁵ is hydrogen, halo, C_{1-6} alkyl or aryl;

G¹ is $-CH_2-CH_2-$, $-CH=CH-$, $-N=N-$, $-C(=O)-CH_2-$ or $CH_2-CH_2-CH_2-$, wherein one or two hydrogen

atoms each independently may be replaced by C₁₋₆ alkyl; and

G² is -CH₂-CH₂-, -CH₂-N(R¹⁴)- or -CH₂-CH₂-CH₂-, wherein one or two hydrogen atoms each independently may be replaced by C₁₋₆ alkyl.

Typical bicyclic amides covered by the definition of R⁵ and R⁶, can be represented by the following formulae:



wherein X⁴ and X⁵ each independently are O or S;

each R¹⁶ independently is hydrogen, C₁₋₆ alkyl or arylC₁₋₆ alkyl;

each R¹⁷ independently is hydrogen, halo, C₁₋₆ alkyl or C₁₋₆ alkyloxy ; and

R¹⁸ is hydrogen, halo, C₁₋₆ alkyl or aryl;

wherein the radicals (d-5), (d-6), (d-7) and (d-8) may be connected to respectively Alk or X by replacing either a hydrogen or a radical R¹⁶ and R¹⁷ by a free bond;

G³ is -CH=CH-CH=CH-, -(CH₂)₄-, -S-(CH₂)₂-, -S-(CH₂)₃-, -S-CH=CH-, -CH=CH-O-, -NH-(CH₂)₂-, -NH-(CH₂)₃-, -NH-CH=CH-, -NH-N=CH-CH₂-, -NH-CH=N- or -NH-N=CH-;

G⁴ is -CH=CH-CH=CH-, -CH=CCl-CH=CH-, -CCl=CH-CH=CH-, -N=CH-CH=CH-, -CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N-, -N=CH-N=CH- or -CH=N-CH=N-.

Further particular heterocyclic ring systems within this subgroup are selected from the group consisting of 2,3-dihydro-2-oxo-1H-benzimidazolyl optionally substituted with C₁₋₆ alkyl; 2-oxo-1-imidazolidinyl optionally substituted with C₁₋₄ alkyl; 2,5-dioxo-1-imidazolidinyl optionally substituted with C₁₋₄ alkyl; 3,4-dihydro-4-oxo-1,2,3-benzotriazin-3-yl; 1-oxo-2(1H-phthalazinyl); 2,3-dihydro-5-oxo-5H-thiazolo-[3,2-a]-pyrimidin-6-yl optionally substituted with C₁₋₄ alkyl; and 5-oxo-5H-thiazolo-[3,2-a]-pyrimidin-6-yl optionally substituted with C₁₋₄ alkyl.

Preferred compounds within the invention are those compounds of formula (I) wherein R¹ is hydrogen or halo; and/or R² is hydrogen or amino; and/or R³ is hydrogen or C₁₋₄ alkyl; and/or R⁴ is hydrogen; and/or

L is a radical of formula (b-1) wherein R⁵ is hydrogen, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanone, aryl or Het; or

L is a radical of formula (b-2) wherein X is O, S or NH and R⁵ is hydrogen, C₁₋₄ alkyl, aryl or Het; or

L is a radical of formula (b-3) wherein Y is NH or a direct bond and R⁸ is hydrogen, C₁₋₄ alkyl, aryl or

C₁₋₄ alkyloxy; or

L is a radical of formula (b-4) wherein Y is NH or a direct bond and R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₄ alkyl or aryl, or R¹⁰ and R¹¹ combined with the nitrogen bearing said R¹⁰ and R¹¹ may form a pyrrolidinyl or piperidinyl radical.


More preferred compounds are those preferred compounds wherein the substituents on the 3 and 4 position of the piperidine ring have the cis-configuration.

Particular preferred compounds are those more preferred compounds wherein R¹ is halo, R² is amino, R³ is C₁₋₄ alkyl, R⁴ is hydrogen and A is a radical of formula (a-1) or (a-2) wherein the carbon atom adjacent to the oxygen atom is optionally substituted with one or two C₁₋₄ alkyl substituents.

Other particular preferred compounds are those more preferred compounds wherein R¹ is halo, R² is amino, R³ is C₁₋₄ alkyl, R⁴ is hydrogen and A is a radical of formula (a-5).


Most preferred compounds are selected from the group consisting of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-(1-oxo-2(1H)phthalazinyl)ethyl]-4-piperidinyl]-7-benzofurancarboxamide, cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[(tetrahydro-2-furanyl)methyl]-4-piperidinyl]-7-benzofurancarboxamide, cis-4-amino-5-chloro-N-[1-[3-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-propyl]-3-methoxy-4-piperidinyl]-2,3-dihydro-7-benzofurancarboxamide, cis-4-amino-5-chloro-N-[1-(2-cyclohexylethyl)-3-methoxy-4-piperidinyl]-2,3-dihydro-7-benzofurancarboxamide, cis-4-amino-5-chloro-N-(1-ethyl-3-methoxy-4-piperidinyl)-2,3-dihydro-7-benzofurancarboxamide, cis-4-amino-5-chloro-N-[1-[2-(2,3-dihydro-7-methyl-5-oxo-5H-thiazolo[3,2-a]pyrimidin-6-yl)ethyl]-3-methoxy-4-piperidinyl]-2,3-dihydro-7-benzofurancarboxamide, cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[3-(1-methylethoxy)propyl]-4-piperidinyl]-7-benzofurancarboxamide, cis-4-amino-5-chloro-2,3-dihydro-N-(3-methoxy-1-methyl-4-piperidinyl)-7-benzofurancarboxamide, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, or from the group selected from cis-5-amino-6-chloro-N-(1-ethyl-3-methoxy-4-piperidinyl)-3,4-dihydro-2H-1-benzopyran-8-carboxamide, cis-5-amino-6-chloro-3,4-dihydro-N-[3-methoxy-1-[2-(1-methylethoxy)ethyl]-4-piperidinyl]-2H-1-benzopyran-8-carboxamide, cis-5-amino-6-chloro-3,4-dihydro-N-[3-methoxy-1-[3-(1-methylethoxy)propyl]-4-piperidinyl]-2H-1-benzopyran-8-carboxamide, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, or from the group selected from cis-5-amino-6-chloro-3,4-dihydro-N-[3-methoxy-1-[(tetrahydro-2-furanyl)methyl]-4-piperidinyl]-2H-1-benzopyran-8-carboxamide, cis-8-amino-7-chloro-N-[1-[3-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)-propyl]-3-methoxy-4-piperidinyl]-2,3-dihydro-1,4-benzodioxin-5-carboxamide, the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof.

In order to simplify the structural representations of the compounds of formula (I) and of certain starting materials and intermediates thereof, the radical



will hereafter be represented by the symbol D.

The compounds of formula (I) can be prepared by N-alkylating a piperidine of formula (II) with an intermediate of formula (III).




W as described in the reaction of (III) with (II) and in the following reaction schemes is an appropriate leaving group such as, for example, halo, preferably, chloro, bromo or iodo, or a sulfonyloxy group, e.g. methanesulfonyloxy, 4-methylbenzenesulfonyloxy and the like leaving groups.

The N-alkylation reaction of (II) with (III) is conveniently conducted in a reaction-inert solvent such as, for example, water, an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene, chlorobenzene, methoxybenzene and the like, an alkanol, e.g. methanol, ethanol, 1-butanol and the like, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like, an ester, e.g. ethyl acetate, γ -butyrolactone and the like, a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like, an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran and the like, a polar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, hexamethylphosphor triamide, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, 1,3-dimethyl-2-imidazolidinone, 1,1,3,3-tetramethylurea, nitrobenzene, 1-methyl-2-pyrrolidinone and the like, or a mixture of such solvents.


The addition of an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, carboxylate, amide, oxide, hydroxide or alkoxide, e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate, calcium oxide, sodium acetate, sodium amide, sodium hydroxide, sodium methoxide and the like or an organic base such as, for example, an amine, e.g. N,N-dimethyl-4-pyridinamine, N,N-diethylethanamine, N-(1-methylethyl)-2-propanamine, 1,4-diazabicyclo-[2,2,2]octane, 4-ethylmorpholine and the like, may be utilized to pick up the acid which is liberated during the course of the reaction. In some instances the addition of a iodide salt, preferably an alkali metal iodide, or a crown ether, e.g. 1,4,7,10,13,16-hexaoxacyclooctadecane and the like, may be appropriate. Stirring and somewhat elevated temperatures may enhance the rate of the reaction. Additionally, it may be advantageous to conduct said N-alkylation under an inert atmosphere such as, for example, oxygen-free argon or nitrogen gas. Alternatively, said N-alkylation may be carried out by applying art-known conditions of phase transfer catalysis reactions. Said conditions comprise stirring the reactants, with an appropriate base and optionally under an inert atmosphere as defined hereinabove, in the presence of a suitable phase transfer catalyst such as, for example, a trialkylphenylmethylammonium, tetraalkylammonium, tetraalkylphosphonium, tetraarylphosphonium halide, hydroxide, hydrogen sulfate and the like catalysts. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction.

In this and the following preparations, the reaction products may be isolated from the reaction mixture and, if necessary, further purified according methodologies generally known in the art such as, for example, extraction, distillation, crystallization, trituration and chromatography.

The compounds of formula (I) can also be prepared by the amidation reaction of an amine of formula




with a carboxylic acid of formula



or a functional derivative thereof, such as a halide, a symmetrical or mixed anhydride or an ester, preferably an activated ester. Said functional derivative may be generated in situ, or if desired, be isolated and further purified before reacting it with the amine of formula (IV). Functional derivatives may be prepared following art-known procedures, for example, by reacting the carboxylic acid of formula (V) with thionyl chloride, phosphorous trichloride, phosphoryl chloride and the like, or by reacting the carboxylic acid of formula (V) with an acyl halide, e.g. acetyl chloride, ethyl carbonochloridate and the like. Or the intermediates (IV) and (V) may be coupled in the presence of a suitable reagent capable of forming amides, e.g. dicyclohexylcarbodiimide, 2-chloro-1-methylpyridinium iodide and the like.


Said amidation reactions may conveniently be carried out by stirring the reactants in a suitable reaction-inert solvent such as, for example, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like, an aromatic hydrocarbon, e.g. methylbenzene and the like, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran and the like or a dipolar aprotic solvent, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide and the like. The addition of a suitable base may be appropriate, in particular a tertiary amine such as, *N,N*-diethylethanamine. The water, the alcohol or the acid which is liberated during the course of the reaction may be removed from the reaction mixture according to methodologies generally known in the art such as, for example, azeotropical distillation, complexation or salt formation. In some instances it may be advantageous to cool the reaction mixture. Further it may be expedient to protect amino or hydroxy groups during the course of the reaction to avoid undesired side reactions. Suitable protecting groups comprise readily removable groups such as, C_{1-6} alkylcarbonyl, C_{1-4} alkyloxycarbonyl, arylmethyl, tertiar butyl and the like protective groups.

The compounds of formula (I) can alternatively be prepared by the reductive *N*-alkylation reaction of an appropriate ketone or aldehyde of formula $L'=O$ (VI), said $L'=O$ being a compound of formula $L-H$ wherein two geminal hydrogen atoms in the C_{1-6} alkanediyl or C_{3-6} cycloalkanediyl moiety are replaced by $=O$, with a piperidine of formula $H-D$ (II).



Said reductive *N*-alkylation reaction may conveniently be carried out by reducing a mixture of the reactants in a suitable reaction-inert solvent. In particular, the reaction mixture may be stirred and/or heated in order to enhance the reaction rate. Suitable solvents are, for example, water; C_{1-6} alkanols, e.g. methanol, ethanol, 2-propanol and the like; esters, e.g. ethylacetate, γ -butyrolactone and the like; ethers, e.g. 1,4-dioxane, tetrahydrofuran, 1,1'-oxybisethane, 2-methoxyethanol and the like; halogenated hydrocarbons, e.g. dichloromethane, trichloromethane and the like; dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, dimethyl sulfoxide and the like; carboxylic acids, e.g. acetic acid, propanoic acid and the like; or a mixture of such solvents. The term "art-known reductive *N*-alkylation procedures" means that the reaction is carried out either with sodium cyanoborohydride, sodium borohydride, formic acid or a salt thereof, e.g. ammonium formate and the like reducing agents, or alternatively under hydrogen atmosphere, optionally at an increased temperature and/or pressure, in the presence of an appropriate catalyst such as, for example, palladium-on-charcoal, platinum-on-charcoal and the like. In order to prevent the undesired further hydrogenation of certain functional groups in the reactants and the reaction products, it may be advantageous to add an appropriate catalyst-poison to the reaction mixture, e.g., thiophene, quinoline-sulphur and the like. In some instances it may also be advantageous to add an alkali metal salt to the reaction mixture such as, for example, potassium fluoride, potassium acetate and the like salts.

The compounds of formula (I) wherein *L* is a radical of formula (b-2) and R^6 is Het can alternatively be prepared according to one of the following alkylation procedures.




In (VII) and (IX) W^1 and W^2 are appropriate leaving groups such as, for example, a halo, e.g. chloro or bromo, a C_{1-6} alkyloxy or a C_{1-6} alkylthio, e.g. methoxy or methylthio in case of W^1 , or a sulfonyloxy group or pyridinium group in case of W^2 .

The alkylation reactions of (VII) with (I-b-2-a) and (VIII) with (IX) can be carried out according to art-known procedures, e.g. by stirring the reactants without a solvent or in an inert organic solvent such as, for


example, an aromatic hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene, and the like, a lower alkanol, e.g. methanol, ethanol, 1-butanol and the like, a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like, an ether, e.g. 1,4-dioxane, 1,1'-oxybisethane, tetrahydrofuran and the like, a polar aprotic solvent, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide, dimethylsulfoxide, nitrobenzene, 1-methyl-2-pyrrolidinone and the like or a mixture of two or more of such solvents. The addition of an appropriate base such as, for example, an alkali or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, alkoxide, hydride, amide or oxide, e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, sodium methoxide, sodium hydride, sodium amide, calcium carbonate, calcium hydroxide, calcium oxide and the like or an organic base, such as, for example, a tertiary amine, e.g. *N,N*-diethylethanamine, *N*-(1-methylethyl)-2-propanamine, 4-ethyl-morpholine and the like, may be utilized to pick up the acid which is liberated during the course of the reaction.

The compounds of formula (I) wherein L is a radical of formula (b-4), said compounds being represented by (I-b-4), can also be prepared by reacting a piperidine of formula (X) with an amine of formula (XI).




In (XI) R^{10} and R^{11} have the same meanings as described hereinbefore.

The compounds of formula (I) wherein L is a radical of formula (b-4) and Y is NR^9 , said compounds being represented by (I-b-4-a), can also be prepared by reacting an amide of formula (XII) with an amine of formula (XIII).




The reactions of (XI) with (X) and (XII) with (XIII) are conveniently conducted in a suitable reaction-inert solvent, such as, for example, a hydrocarbon, e.g. benzene, methylbenzene, a ketone, e.g. acetone, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane, an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran and the like, a polar aprotic solvent, e.g. *N,N*-dimethylacetamide, *N,N*-dimethylformamide or a mixture of such solvents. An appropriate base such as for example, an alkali metal carbonate, sodium hydride or an organic base such as for example, *N,N*-diethylethanamine or *N*-(1-methylethyl)-2-propanamine may be utilized to pick up the acid which is liberated during the course of the reaction. Somewhat elevated temperatures may enhance the rate of the reaction.

The compounds of formula (I) wherein L is a radical of formula (b-3) and Y is NR^9 , said compounds being represented by formula (I-b-3-a), may also be prepared by reacting a carboxylic acid of formula (XIV) or a functional derivative with an amine of formula (XIII).



The reaction of (XIV) with (XIII) may generally be conducted following the same procedures as previously described for the amidation reaction of (V) with (IV).

The compounds of formula (I) wherein L is NC-CH₂-CH₂-, said compounds being represented by (I-c), can also be prepared by alkylating a piperidine of formula (II) with acrylonitrile (XV) in a reaction-inert solvent such as, for example, an aromatic hydrocarbon, e.g. benzene, methylbenzene and the like, an alkanol, e.g. methanol, ethanol, 2-propanol and the like, a ketone, e.g. 2-propanone and the like, an ether, e.g. tetrahydrofuran and the like, or a mixture of such solvents.



The compounds of formula (I) can also be converted into each other following art-known procedures of functional group transformation. Some examples of such procedures will be cited hereinafter.

Compounds of formula (I) containing a hydroxy function may be O-alkylated according to art-known O-alkylation procedures, e.g. by stirring the former with an appropriate alkylating agent, if desired, in the presence of sodium hydride.

Compounds of formula (I) bearing a protective dioxolan ring may be deacetalized to yield the corresponding oxo compounds. Said deacetalization may be conducted following procedures widely known in the art such as, for example, by reacting the starting materials in an acidic aqueous medium.


The compounds of formula (I) containing a cyano substituent can be converted into the corresponding amines by stirring and, if desired, heating the starting cyano compounds in a hydrogen containing medium in the presence of an appropriate catalyst such as, for example, platinum-on-charcoal, Raney nickel and the like catalysts and optionally in the presence of a base such as, for example, an amine e.g. N,N-diethylethanamine and the like, or a hydroxide, e.g. sodium hydroxide and the like. Suitable solvents are, for example, alkanols, e.g. methanol, ethanol and the like; ethers, e.g. tetrahydrofuran and the like or a mixture of such solvents.

The compounds of formula (I) may also be converted to the corresponding N-oxide forms following art-known procedures for converting a trivalent nitrogen to its N-oxide-form. Said N-oxidation reaction may generally be carried out by reacting the starting material of formula (I) with an appropriate organic or inorganic peroxide. Appropriate inorganic peroxides comprise, for example, hydrogen peroxide, an alkali metal or earth alkali metal peroxide, e.g. sodium peroxide, potassium peroxide, barium peroxide and the like; appropriate organic peroxides may comprise peroxy acids such as, for example, benzenecarboperoxoic acid or halo substituted benzenecarboperoxoic acid, e.g. 3-chlorobenzenecarboperoxoic acid and the like, peroxyalkanoic acids, e.g. peroxyacetic acid and the like, alkylhydroperoxides, e.g. *t*-butyl hydroperoxide and the like.

Said N-oxidation may be carried out in a suitable solvent such as, for example, water, a lower alkanol, e.g. methanol, ethanol, propanol, butanol and the like; a hydrocarbon, e.g. benzene, methylbenzene, dimethylbenzene and the like; a ketone, e.g. 2-propanone, 2-butanone and the like, a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like or mixtures of such solvents. In order to enhance the reaction rate, it may be appropriate to heat the reaction mixture.


Some of the intermediates and starting materials in the foregoing preparations are known compounds while others are novel. They may be prepared according to art-known methodologies of preparing said known or similarly known compounds. Some procedures for preparing such intermediates will be described hereinafter in more detail.

The intermediates of formula (II) may be derived from an appropriately substituted piperidine of formula (XVI) by reacting the latter with a reagent of formula (V) or a functional derivative thereof, following the amidation procedures described for the preparation of (I) starting from (IV) and (V), and subsequently removing of the protective group P¹ in the thus obtained intermediate (XVII) following art-known procedures, e.g. by hydrolysis in an acidic or an alkaline medium or by catalytic hydrogenation, depending upon the nature of P¹.




10 In the reaction of (XVI) with (V) and in the following reaction schemes P¹ represents a suitable protective group which is readily removable by hydrogenation or hydrolysis. Preferred protective groups may for example be, hydrogenolyzable groups, e.g. phenylmethyl and the like or hydrolyzable groups, such as C₁₋₄alkyloxycarbonyl, e.g. benzyloxycarbonyl and the like.

15 The intermediates of formula (IV) can be derived from an appropriately substituted piperidine of formula (XVIII) by alkylating the latter with an appropriate reagent L-W (III), following the alkylation procedures described for (I) starting from (II) and (III) and, subsequently removing the protective group P¹ in the thus obtained intermediate following art-known procedures described hereinbefore.




30 In general, the piperidines (IV), (XVI) and (XVIII) used as starting materials, can be prepared following procedures analogous to those described in Drug Development Research 8, 225-232 (1986) and in the Eur. Pat. No. 76,530 which corresponds to U.S. Application Serial No. 403,603.

35 The intermediates of formula (V) and the functional derivatives thereof can be prepared from an intermediate of formula (XX), wherein W³ represents hydrogen or an appropriate reactive leaving group such as for example, halo, e.g. chloro, bromo, iodo and the like, by treating intermediate (XX) with an alkyl lithium, e.g. n-butyl lithium, methyl lithium and the like, an alkali metal, e.g. lithium, sodium and the like, a transition metal, e.g. magnesium, zinc, cadmium and the like or an amide, e.g. sodiumamide and the like, followed by treatment with CO₂ or a reagent of formula L¹-C(=O)-L¹ wherein L¹ represents an appropriate leaving group such as, for example, C₁₋₆alkyloxy, halo and the like.




45 Said reaction can conveniently be carried out in a reaction-inert solvent such as for example, an aliphatic hydrocarbon, e.g. pentane, hexane, cyclohexane and the like, an aromatic solvent, e.g. benzene, chlorobenzene and the like, an ether, e.g. tetrahydrofuran, 1,4-dioxane and the like or a mixture of such solvents and optionally in the presence of an amine, e.g. ethanamine, N,N-diethylethanamine, N,N,N',N'-tetramethylethylenediamine and the like.

The intermediates of formula (XX) wherein W^3 is a reactive leaving group, said W^3 being represented by W^{3-a} and said intermediates being represented by (XX-a), can in turn be obtained from (XXI) following art-known halogenation procedures optionally followed by the separation of the undesired isomers.




For example, an intermediate of formula (XXI) can be halogenated with a dihalide, e.g. chlorine, bromine and the like, optionally in the presence of a catalyst such as, a Lewis acid, e.g. ferric chloride, ferric bromide, aluminum chloride and the like. Intermediate (XXI) can also be halogenated with *N*-haloamides, e.g. *N*-chlorosuccinimide, *N*-bromosuccinimide and the like. In some instances the reaction can be catalyzed by the addition of acids, e.g. acetic acid, hydrochloric acid and the like. Said halogenation reactions can conveniently be carried out in a reaction-inert solvent such as, for example, water, an aliphatic hydrocarbon, e.g. pentane, hexane, cyclohexane and the like, an aromatic solvent, e.g. benzene, methylbenzene and the like, a halogenated hydrocarbon, e.g. dichloromethane, tetrachloromethane and the like, or an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran and the like.

The intermediates of formula (XXI) wherein R^1 is other than hydrogen, said R^1 being represented by R^{1-a} and said intermediates by (XXI-a), can be prepared by halogenation or sulfonylation of an intermediate of formula (XXII).




The halogenation reaction can be carried out according to the halogenation procedures described hereinbefore for the halogenation of (XXI). The sulfonylation reaction can be carried out by treating intermediate (XXII) with, for example, a sulfonyl halide, e.g. C_{1-6} alkylsulfonyl chloride, C_{1-6} alkylsulfonyl bromide and the like, optionally in the presence of a catalyst such as, a Lewis acid, e.g. ferric chloride, ferric bromide, aluminum chloride and the like; or by halosulfonation with chlorosulfuric acid followed by treatment with ammonia.

The starting materials of formula (XXII) wherein A is $-CH_2-CH_2-$, $-CH_2-CH_2-CH_2-$, or $-CH_2-CH_2-CH_2-CH_2-$, wherein one or two hydrogen atoms may be replaced by C_{1-6} alkyl, said A being represented by A^1 , and said intermediates by formula (XXII-a), can be obtained by cyclizing an intermediate of formula (XXIII) in the presence of an acid such as, for example, hydrochloric acid, hydrobromic acid and the like, or mixtures thereof with acetic acid.



10 In intermediate (XXIII) and throughout the following description and reaction schemes R¹⁹ is C₁-₄ alkyl.


The intermediates of formula (XXIII), in turn, can be prepared by deprotecting the functionalized alcohol in intermediate (XXIV).



20 In formula (XXIV) P² is a protective group such as for example, tetrahydropyranyl, tertiar butyl, phenylmethyl and the like. These protective groups are readily removable by hydrolysis with for example, an acid, e.g. hydrochloric acid, hydrobromic acid, acetic acid and the like or by catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst. In case R² is amino, it may be expedient to protect this group during the course of the above and the following reactions to avoid undesired side reactions. Suitable protective groups are, for example, C₁-₆ alkylcarbonyl, C₁-₆ alkyloxycarbonyl, benzyloxycarbonyl and arylmethyl groups. The removal of the protective group may generally be carried out by deblocking, for example, a C₁-₆ alkylcarbonyl group with an appropriate acid or base in an anhydric or aqueous organic solvent or in water; or by catalytic hydrogenation in the presence of hydrogen and an appropriate catalyst


25 depending upon the nature of the protective group.

The intermediates of formula (XXIV) can be obtained by reduction of an intermediate of formula (XXV).




35 It is to be understood that in formula (XXV) and the subsequent formulae one or two hydrogen atoms of the carbon chain may be replaced by a C₁-₆ alkyl radical, and n can be 0, 1 or 2. The double bond of formula (XXV) may be reduced by catalytic hydrogenation in a suitable solvent, e.g. methanol or ethanol and the like in the presence of hydrogen and an appropriate catalyst e.g. platinum-on-charcoal, palladium-on-charcoal, Raney nickel and the like, optionally at an increased temperature and/or pressure.

40 The intermediates of formula (XXV) can be prepared by reacting an aldehyde (XXVI) with a suitable ylide such as, for example, a phosphorus ylide (e.g. R²⁰ and R²¹ are aryl or alkyl: Wittig reaction) or an ylide prepared from a phosphonate (e.g. R²⁰ is alkoxy and R²¹ is O⁻: Horner-Emmons reaction).




15 Said ylide can be obtained by treating a phosphonium salt or a phosphonate with an appropriate base such as, for example, potassium tert. butoxide, n.butyl lithium, sodium amide, sodium hydride and the like bases under an inert atmosphere and in a reaction-inert solvent such as, for example, an ether, e.g. tetrahydrofuran, 1,4-dioxane and the like.

20 The intermediates of formula (XXVI) can conveniently be obtained from an alkoxybenzene derivative of formula (XXVII) following art-known formylation procedures, optionally followed by the separation of the undesired isomers.




35 For example, the alkoxybenzene derivative of formula (XXVII) can be formylated by reaction with an appropriate base such as, for example, an alkyl lithium, e.g. methyl lithium, n.butyl lithium, and the like, and subsequently reacting the thus obtained metalated alkoxybenzene derivative with a formamide, e.g. *N,N*-dimethylformamide, *N*-methyl-*N*-phenylformamide, and the like. Said formylation may also be conducted under Vilsmeier-Haack (phosphoryl chloride, formamide) or Gattermann (zinc(II)cyanide, hydrochloric acid) conditions in an acidic medium.

40 Alternatively, the starting intermediates of formula (XXII), wherein A is $-\text{CH}_2-\text{CH}_2-$, wherein one or two hydrogen atoms may be replaced by C_{1-6} alkyl, said intermediates being represent by formula (XXII-a-1), can be obtained by cyclizing an intermediate of formula (XXIII-a-1) in an acidic medium according to the procedures described in J. Het. Chem., 17, 1333 (1980).




55 It is to be understood that in formula (XXIII-a-1) and (XXII-a-1) one or two hydrogen atoms of the ethyl or tetrahydrofuran moiety may be replaced by a C_{1-6} alkyl radical. The desired intermediates of formula (XXIII-a-1) can be obtained from an alkoxybenzene derivative of formula (XXVII) by reaction of the latter with an ethylene oxide derivative in a reaction inert solvent such as, for example, an ether, e.g. tetrahydrofuran, 1,4-dioxane, and the like in the presence of a base. Appropriate bases are, for example, alkyl lithium, e.g. methyl lithium, n.butyl lithium and the like.

The starting intermediates of formula (XXII), wherein R^2 is amino and A is $-\text{CH}_2-\text{CH}_2-\text{O}-$, wherein one or two hydrogen atoms may be replaced by C_1-C_6 alkyl, said intermediates being represented by formula (XXII-a-5), can be obtained by reduction of the azide group of formula (XXVIII) to the corresponding amino group.




15 Said reduction reaction can be carried out with an appropriate reductant such as, for example, lithium aluminum hydride or 1,2-ethanedithiol in a reaction-inert solvent. It is to be understood that in formula (XXII-a-5) and the subsequent formulae (XXVIII), (XXIX) and (XXX) one or two hydrogen atoms of the dioxepin moiety may be replaced by a C_1-C_6 alkyl radical.

20 The above intermediates of formula (XXVIII) can be prepared, in two steps, by lithiation of dihydrobenzodioxin of formula (XXX) with an alkyl lithium, e.g. n-butyl lithium and the like, followed by a treatment with sodium azide.




35 The starting intermediates of formula (XXII), wherein R^2 is amino and A is $-\text{CH}_2-\text{CH}_2-\text{CH}_2-\text{O}-$, wherein one or two hydrogen atoms may be replaced by C_1-C_6 alkyl, said intermediates being represented by formula (XXII-a-6), can be prepared by a cycloalkylation reaction of 3-nitrocatechol (XXXI) with 1,3-dibromopropane (XXXII) according to the procedures described in J. Med. Chem., 31, 1934 (1988). Subsequent reduction of the nitro-group of formula (XXXIII) following art-known nitro-to-amino reduction procedures provide the aniline derivative (XXII-a-6).



It is to be understood that in formula (XXII-a-6), (XXXII) and (XXXIII), one or two hydrogen atoms of the alkyl or dioxepin moiety may be replaced by a C_1-C_6 alkyl radical.


The starting materials of formula (XXI), wherein R^1 is chloro, R^2 is amino and A is $-\text{CH}_2-\text{CH}_2-\text{O}-$, said intermediates being represented by (XXI-a-5), can be prepared as described in J. Chem. Soc., 1315 (1955), by reduction of the corresponding nitro-derivative of formula (XXXIV), following art-known nitro-to-amino reduction procedures such as, for example, catalytic hydrogenation in a suitable solvent in the presence of hydrogen and an appropriate catalyst, e.g. platinum-on-charcoal and the like. The nitrobenzodioxin derivative (XXXIV) can in turn be obtained by diazotation of the aminodinitrobenzodioxin derivative of formula

(XXXV), dediazonation and nucleophilic aromatic substitution with chloride.




15 It is to be understood that in formula (XXI-a-5) and the subsequent formulae (XXXIV) and (XXXV) one or two hydrogen atoms of the dioxin moiety may be replaced by a C_{1-6} alkyl radical.

The basic intermediates of formula (V) can also be prepared by hydrolyzing the ester group of formula (XXXVI) in a basic or acidic aqueous medium.




In (XXXVI) and throughout the following description and reaction schemes R^{22} is a C_{1-6} alkyl radical.


35 The above esters of formula (XXXVI) in turn can be obtained by halogenation or sulfonylation of the intermediates of formula (XXXVII) according to the procedures described hereinbefore for the preparation of the intermediates of formula (XXI-a) from (XXII).



50 The intermediates of formula (XXXVII), wherein A is $-C(CH_3)_2-CH_2-$, said intermediates being represented by formula (XXXVII-a-1) can be obtained by cyclizing the phenyl allyl intermediate (XXXVIII), in the presence of an acid, for example, formic acid, acetic acid, hydrogen bromide and the like, or a mixture of these acids.




The above phenyl allyl intermediate (XXXVIII) can be prepared by a Claisen rearrangement of a phenyl allyl ether of formula (XXXIX).




Said reaction can be carried out in a reaction-inert solvent at a somewhat elevated temperature, in particular the reflux temperature of the reaction mixture. Suitable solvents are, for example, aliphatic or aromatic hydrocarbons, e.g. methylbenzene, phenylbenzene and the like, halogenated hydrocarbons, e.g. chlorobenzene and the like, alcohols, e.g. cyclohexanol and the like, ethers, e.g. 1,1'-oxybisethane, 1,1'-oxybisbenzene and the like, amines, e.g. *N,N*-dimethylaniline and the like; dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, 1-methyl-2-pyrrolidinone and the like.

The phenyl allyl ether of formula (XXXIX) can in turn be prepared by the *O*-alkylation reaction of a phenol intermediate of formula (XXXX) with an alkylating reagent of formula (XXXXI) following art-known *O*-alkylation procedures.




In formula (XXXXI) W is defined as described hereinbefore for intermediate (III). Said *O*-alkylation reaction can conveniently be carried out by mixing the reactants, optionally in a reaction-inert solvent such as, for example, water, an aromatic solvent, e.g. benzene and the like, a *C*₁₋₆ alkanol, e.g. ethanol and the like, a ketone, e.g. 2-propanone and the like, an ether, e.g. tetrahydrofuran and the like, or a dipolar aprotic solvent, e.g. *N,N*-dimethylformamide and the like. The addition of an appropriate solvent compatible base such as, for example potassium carbonate, sodium hydroxide or sodium hydride and the like may optionally be used to pick up the acid which is formed during the course of the reaction.

The intermediates of formula (XXXVI), wherein A is -CH₂-CH₂-CH₂- wherein one or two hydrogen atoms may be replaced by *C*₁₋₆ alkyl, said intermediate being represented by formula (XXXVI-a-2), can be obtained by reduction of a 2H-benzopyran of formula (XXXXII) following the reduction procedures described hereinbefore for the preparation of the intermediates of formula (XXIV).




10 It is to be understood that in formula (XXXVI-a-2), (XXXXII) and (XXXXIII) one or two hydrogen atoms of the pyran moiety or carbon chain may be replaced by C₁₋₆ alkyl.

The intermediates of formula (XXXXII) can be prepared by a Claisen rearrangement of the phenylether of formula (XXXXIII) followed by a cyclization reaction to obtain the intermediate of formula (XXXXII).



25 Said reaction can be carried out according to similar reacting procedures as described in Elderfield, Heterocyclic Compounds; Vol. 2, pages 393-418. Preferably the rearrangement is carried out in a reaction-inert solvent at temperatures above 100°C. Suitable solvents are for example, hydrocarbons, e.g. phenylbenzene, diphenylmethane, naphthalene, decahydronaphthalene and the like, halogenated hydrocarbons, e.g. chlorobenzene and the like, alcohols, e.g. cyclohexanol and the like, ethers, e.g. 1,1'-oxybisbenzene and the like.

30 In some instances the Claisen rearrangement of the phenylether of formula (XXXXIII) results in a benzofuran of formula (XXXXIV) instead of a 2H-benzopyran of formula (XXXXII). A benzofuran of formula (XXXXIV) is obtained when the Claisen rearrangement reaction is carried out in the presence of an appropriate base such as for example, an alkali metal or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide and the like, or in an appropriate solvent such as for example, an amine, e.g. pyridine, quinoline, N,N-diethylbenzenamine and the like, a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, and the like.



55 The intermediates of formula (II) and (XVII) wherein R¹, R², R³, R⁴, A and P¹ have the above described meanings are deemed to be novel, and as such they represent an additional feature of the present invention. In addition the intermediates of formula (V) and (XXXVI) wherein R¹ is chloro and R² is amino are believed to be novel compounds and constitute a further aspect of the invention.

Pure stereochemically isomeric forms of the compounds of formula (I) and the intermediates of formula (II) may be obtained by the application of art-known procedures. Diastereoisomers may be separated by physical separation methods such as selective crystallization and chromatographic techniques, e.g. counter current distribution, and enantiomers may be separated from each other by the selective crystallization of their diastereomeric salts with optically active acids or their optically activated derivatives.

It is evident that the cis and trans diastereomeric racemates may be further resolved into their optical isomers, cis(+), cis(-), trans(+), and trans(-) by the application of methodologies known to those skilled in the art.

Pure stereochemically isomeric forms may also be derived from the corresponding pure stereochemically isomeric forms of the appropriate starting materials, provided that the reaction occurs stereospecifically.

The compounds of formula (I) containing an alkene moiety may be present in a "E" or "Z" form, said E- and Z-notation having the meanings described in J. Org. Chem., 35, 2849-2868 (1970).

The compounds of formula (I) and the intermediates of formula (II), the N-oxide forms, the pharmaceutically acceptable salts and possible stereoisomeric forms thereof possess favourable gastrointestinal motility stimulating properties. In particular the present compounds show significant motility enhancing effects on the colon. The latter property is clearly evidenced by the results obtained in the "colon ascendens induced contractions" test described hereinafter.

The stimulatory effect of the subject compounds of formula (I) and (II) on the motility of the gastrointestinal system may further be evidenced by, for example, the various test models described in The Journal of Pharmacology and Experimental Therapeutics, 234, 775-783 (1985) and in Drug Development Research 8, 243-250 (1986). The "Gastric emptying of a liquid meal in rats" test described in the latter article and the "Gastric emptying of an a-caloric meal in conscious dog after administration of lidamidine" test further revealed that a representative number of compounds also significantly accelerated gastric emptying.

In addition, the present compounds of formula (I) and (II), the N-oxide forms, the pharmaceutically acceptable acid addition salts and possible stereoisomeric forms thereof have a particular receptor binding profile. Some groups of compounds within the present invention, particularly those wherein the radical A is not substituted with C₁₋₆ alkyl have a poor 5HT₃ antagonistic activity as induced by high doses of serotonin on the guinea pig ileum. The most compounds of the invention do not show any apparent marked receptor-binding affinity with serotonergic-5HT₁ and serotonergic-5HT₂ receptors and have little or no dopaminergic antagonistic activity.

In view of their useful gastrointestinal motility enhancing properties the subject compounds may be formulated into various forms for administration purposes.

To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in base or acid addition salt form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which carrier may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wetting agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause a significant deleterious effect to the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on, as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base form, are obviously more suitable in the preparation of aqueous compositions.

It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification

and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, 5 teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

In view of their capability to stimulate the motility of the gastrointestinal system and, in particular their capacity to enhance the motility of the colon, the subject compounds are useful to normalize or to improve the gastric and intestinal emptying in subjects suffering from a disturbed motility, e.g. a decreased peristalsis of the stomach and/or of the small and/or large intestine.

10 In view of the utility of the compounds of the present invention, there is provided a method of treating warm-blooded animals suffering from motility disorders of the gastrointestinal system such as, for example, gastroparesis, flatulent dyspepsia, non-ulcer dyspepsia, pseudo-obstruction, and in particular impaired colonic transit. Said method comprises the systemic administration of an effective gastrointestinal motor-stimulating amount of a compound of formula (I), a N-oxide, a pharmaceutically acceptable acid addition 15 salt or a possible stereoisomeric form thereof, to warm-blooded animals. Some particular compounds of the invention also possess therapeutic value in the treatment of upper bowel motility and gastroesophageal reflux disorders.

Those of skill in the pertinent art could easily determine the effective motor-stimulating amount from the test results presented hereinafter.

20 In general it is contemplated that an effective amount would be from 0.001 mg/kg to 10 mg/kg body weight, and more preferably from 0.01 mg/kg to 1 mg/kg body weight. The following examples are intended to illustrate the invention in all its aspects. Unless otherwise stated all parts therein are by weight.

Experimental Part

A. Preparation of the intermediates


Example 1

30 a) To a solution of 8.1 parts of 4-amino-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid in 218 parts of trichloromethane and 3.43 parts of N,N-diethylethanamine were added dropwise 3.63 parts of ethyl chloroformate, keeping the temperature below 10°C. After stirring for 1/2 hour at 10°C, the whole was added to a solution of 6.26 parts of ethyl 4-amino-3-methoxy-1-piperidinecarboxylate in 145 parts of trichloromethane at 10°C. Stirring was continued for 1/2 hour at room temperature. The reaction 35 mixture was washed with water, NaOH 5% and water and was then dried, filtered and evaporated. The residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 12.3 parts (93.2%) of ethyl cis-4-[(4-amino-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofuranyl)carbonylamino]-3-methoxy-1-piperidinecarboxylate (interm. 1).

40 b) A mixture of 12.3 parts of intermediate 1, 15.9 parts of potassium hydroxide and 156 parts of 2-propanol was stirred for 12 hours at reflux temperature. The reaction mixture was evaporated and water was added to the residue. The whole was evaporated again and the residue was diluted with water. The product was extracted with dichloromethane (2x) and the combined extracts were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH(NH₃) 90:10). The eluent of the desired fraction was evaporated and the residue was suspended in 2,2'-oxybispropane. 45 The product was filtered off and dried, yielding 7.24 parts (71.0%) of cis-4-amino-5-chloro-2,3-dihydro-N-(3-methoxy-4-piperidinyl)-2,2-dimethyl-7-benzofurancarboxamide; mp. 179.3°C (interm. 5).

In a similar manner there were also prepared the intermediates listed in Table 1.

Table 1



Int. No.	R ³	-O-A-	mp. (°C)
2*	-CH ₃	-O-(CH ₂) ₂ -	210.9
3	-H	-O-(CH ₂) ₂ -	260.4
4	-CH ₃	-O-(CH ₂) ₂ -O-	-
5	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	179.3
6	-CH ₃	-O-CH(CH ₃)-CH ₂ -	199.7
7	-CH ₃	-O-(CH ₂) ₃ -	225.2

* note : for intermediate no. 2, no water was added to the residue.

Example 2

a) A solution of 9.1 parts of 5-chloro-2,3-dihydro-4-benzofuranamine [described in J. Het. Chem., 17(6) 1333 (1980)], 9.6 parts of N-bromosuccinimide and 130.5 parts of benzene was stirred for 1 hour at reflux temperature. The solvent was evaporated and the residue was dissolved in 387.4 parts of trichloromethane. The solution was washed with water (2x200 parts). The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; C₆H₁₄/CH₂Cl₂ 50:50). The eluent of the desired fraction was evaporated, yielding 11.8 parts (87.9%) of 7-bromo-5-chloro-2,3-dihydro-4-benzofuranamine (interm. 8).

b) To a cooled (-70 °C) and stirred mixture of 15.6 parts of a solution of n.butyllithium in hexane 2.5M and 44.5 parts of tetrahydrofuran was added dropwise a solution of 4 parts of intermediate 8 in 26.7 parts of tetrahydrofuran under a nitrogen flow. The reaction mixture was stirred for 1 hour at about -60 °C and was poured into a saturated suspension of carbondioxide (ice) in 44.5 parts of tetrahydrofuran. The whole was allowed to warm up to room temperature while being stirred and 80 parts of water were added. The aqueous layer was neutralized with hydrochloric acid and the formed precipitate was filtered off and dried in vacuo at 60 °C, yielding 1.1 parts (32.2%) of 4-amino-5-chloro-2,3-dihydro-7-benzofurancarboxylic acid; mp. 258.4 °C (interm. 9). In a similar manner there was also prepared: 8-amino-7-chloro-2,3-dihydro-1,4-benzodioxin-5-carboxylic acid (interm. 10).

Example 3

a) A mixture of 40 parts of methyl 4-(acetylamino)-5-chloro-2-(2-propynyloxy)benzoate and 172 parts of phenoxybenzene was stirred for 45 min. at 230 °C. After cooling, the reaction mixture was poured into petroleumether. The organic layer was separated, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH 97:3). The eluent of the desired fractions was evaporated and the residue was crystallized from acetonitrile, yielding 11.9 parts (33.8%) of methyl 5-(acetylamino)-6-chloro-2H-1-benzopyran-8-carboxylate (interm. 11).

b) A mixture of 31.3 parts of intermediate 11, 31 parts of *N,N*-diethylethanamine and 395 parts of methanol was hydrogenated at normal pressure and room temperature with 4 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was suspended in water and the product was extracted with dichloromethane (2x). The combined extracts were washed with water, dried, filtered and evaporated. The residue was purified twice by column chromatography (silica gel; CH₂Cl₂/CH₃OH 97.5:2.5). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 19.1 parts (69.7%) of methyl 5-(acetylamino)-3,4-dihydro-2H-1-benzopyran-8-carboxylate; mp. 175.1 °C (interm. 12).

c) A mixture of 19.1 parts of intermediate 12, 10.22 parts of *N*-chlorosuccinimide and 237 parts of acetonitrile was stirred for 1 hour at reflux temperature. After cooling, the reaction mixture was poured into 300 parts of water. The product was extracted with dichloromethane (2x) and the combined extracts were washed with water, dried, filtered and evaporated. The residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 17.8 parts (81.5%) of methyl 5-(acetylamino)-6-chloro-3,4-dihydro-2H-1-benzopyran-8-carboxylate; mp. 184.2 °C (interm. 13).

d) A mixture of 1.34 parts of intermediate 13, 2.62 parts of potassium hydroxide and 20 parts of water was stirred for 3 hours at reflux temperature. After cooling, the reaction mixture was acidified to pH 4 with concentrated hydrochloric acid. The precipitate was filtered off and dried, yielding 0.65 parts (60.7%) of 5-amino-6-chloro-3,4-dihydro-2H-1-benzopyran-8-carboxylic acid; mp. 225.9 °C (interm. 14).

Example 4

a) To a solution of 104.6 parts of methyl 2-hydroxy-4-(acetylamino)benzoate in 470 parts of *N,N*-dimethylformamide were added portionwise 24 parts of a dispersion of sodium hydride in mineral oil (50%) under a nitrogen atmosphere. After stirring for 1 hour at room temperature, there was added a solution of 55.2 parts of 3-chloro-2-methyl-1-propene in 47 parts of *N,N*-dimethylformamide. Stirring was continued for 3 days at 50 °C. The reaction mixture was evaporated and the residue was dissolved in dichloromethane. This solution was washed with water, sodium hydroxide 10% and water and was then dried, filtered and evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 65.8 parts (50.0%) of methyl 4-(acetylamino)-2-[(2-methyl-2-propenyl)oxy]benzoate (interm. 15).

b) A mixture of 72 parts of intermediate 15 and 226 parts of 1-methyl-2-pyrrolidinone was stirred for 1.5 hour at reflux temperature. After cooling, the reaction mixture was poured into ice-water. The product was extracted with dichloromethane (2x) and the combined extracts were washed with water, dried, filtered and evaporated. The residue was crystallized from 2,2'-oxybispropane. The product was filtered off and dried, yielding 35.4 parts (49.8%) of methyl 4-(acetylamino)-2-hydroxy-3-(2-methyl-2-propenyl)benzoate. The mother liquor was evaporated and the residue was successively suspended in water and recrystallized from 2,2'-oxybispropane, yielding an additional 17.6 parts (24.8%) of methyl 4-(acetylamino)-2-hydroxy-3-(2-methyl-2-propenyl)benzoate. Total yield: 53.0 parts (74.6%) (interm. 16).

c) A mixture of 126 parts of intermediate 16 and 1220 parts of formic acid was stirred for 20 hours at reflux temperature. After cooling, the reaction mixture was poured into ice-water and the whole was extracted with dichloromethane (2x). The combined extracts were washed with sodium hydroxide 10% and water and were then dried, filtered and evaporated. The residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 105.5 parts (83.8%) of methyl 4-(acetylamino)-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylate (interm. 17).

d) A mixture of 10.5 parts of intermediate 17, 5.87 parts of *N*-chlorosuccinimide and 158 parts of acetonitrile was stirred for 1 hour at reflux temperature. After cooling, the reaction mixture was poured into ice-water. The product was extracted with dichloromethane (2x) and the combined extracts were dried, filtered and evaporated. The residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 11.9 parts (99.9%) of methyl 4-(acetylamino)-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylate (interm. 18).

e) A mixture of 11.9 parts of intermediate 18, 22.4 parts of potassium hydroxide and 200 parts of water was stirred for 3 hours at reflux temperature. After cooling, the reaction mixture was acidified to pH 4-5. The precipitate was filtered off and dried, yielding 8.1 parts (83.8%) of 4-amino-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid (interm. 19).

B. Preparation of the final compounds

Example 5

- 5 A mixture of 3.9 parts of intermediate 2, 2.54 parts of sodium carbonate, one crystal of potassium iodide and 144 parts of 4-methyl-2-pentanone was stirred for 1 hour at reflux temperature using a water separator. After the addition of 3.2 parts of 1-(2-chloroethyl)-3-ethyl-2,3-dihydro-1H-benzimidazol-2-one, stirring was continued overnight at reflux temperature. The reaction mixture was washed with water. The organic layer was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 96:4). The eluent of the desired fraction was evaporated and the residue was crystallized from 2,2'-oxybispropane. The product was dried in vacuo at 70 °C, yielding 2.30 parts (37.3%) of cis-4-amino-5-chloro-N-[1-[2-(3-ethyl-2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)ethyl]-3-methoxy-4-piperidinyl]-2,3-dihydro-7-benzofurancarboxamide; mp. 173.7 °C (comp. 1).

15 Example 6

- A mixture of 4.2 parts of 3-(2-bromoethyl)-2-methyl-4H-quinazolin-4-one monohydrobromide, 3.3 parts of intermediate 2, 4.24 parts of sodium carbonate, 160 parts of 4-methyl-2-pentanone and a few crystals of potassium iodide was stirred for 20 hours at reflux temperature. The solvent was evaporated and the residue was partitioned between trichloromethane and water. The organic layer was washed with water, dried, filtered and evaporated. The residue was purified twice by column chromatography (silica gel; $\text{CHCl}_3/\text{CH}_3\text{OH}$ 97:3 ; HPLC; silicagel; $\text{C}_6\text{H}_5\text{-CH}_3/\text{i. C}_3\text{H}_7\text{OH}$ 80:20). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile. The product was filtered off and dried in vacuo at 60 °C, yielding 3.10 parts (60.5%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-(2-methyl-4-oxo-3(4H)-quinazolinyl)ethyl]-4-piperidinyl]-7-benzofurancarboxamide; mp. 274.9 °C (comp. 30).

Example 7

- 30 A mixture of 4.07 parts of intermediate 7, 3.82 parts of sodium carbonate and 200 parts of 4-methyl-2-pentanone was stirred and refluxed (with water separation) for 1 hour. There were added 2.7 parts of 6-chloro-2-(3-chloropropyl)-2H-pyridazin-3-one and stirring at reflux temperature was continued overnight. The reaction mixture was evaporated and the residue was taken up in dichloromethane. This solution was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}(\text{NH}_3)$ 95:5). The eluent of the desired fraction was evaporated and the residue was solidified in 2,2'-oxybispropane. The product was filtered off and dried, yielding 3.9 parts (63.7%) of cis-5-amino-6-chloro-N-[1-[3-(3-chloro-1,6-dihydro-6-oxo-1-pyridazinyl)propyl]-3-methoxy-4-piperidinyl]-3,4-dihydro-2H-benzopyran-8-carboxamide; mp. 149.5 °C (comp. 136).

Example 8

- 40 A mixture of 3.4 parts of intermediate 7, 3.16 parts of tetrahydro-2-furanmethanol methanesulfonate (ester), 80 parts of 4-methyl-2-pentanone and 1.58 parts of sodium carbonate was stirred and refluxed (with water separation) for 30 hours. The reaction mixture was evaporated and the residue was diluted with water. The product was extracted with dichloromethane (2x) and the combined extracts were washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}$ 95:5). The eluent of the desired fraction was evaporated and the residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 2.44 parts (57.6%) of cis-5-amino-6-chloro-3,4-dihydro-N-[3-methoxy-1-[(tetrahydro-2-furanyl)methyl]-4-piperidinyl]-2H-1-benzopyran-8-carboxamide; mp. 158.1 °C (comp. 76).

50 Example 9

- A mixture of 3.53 parts of intermediate 5, 2.1 parts of 1-(3-chloropropyl)-3-ethyl-2-imidazolidinone, 94 parts of N,N-dimethylformamide and 1.58 parts of sodium carbonate was stirred for 20 hours at 70 °C. The reaction mixture was evaporated and the residue was diluted with water. The product was extracted with dichloromethane (2x) and the combined extracts were washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; $\text{CH}_2\text{Cl}_2/\text{CH}_3\text{OH}(\text{NH}_3)$ 96:4). The eluent of the desired fraction was evaporated and the residue was converted into the ethanedioate salt in 2-propanol.

The product was filtered off and dried, yielding 4.18 parts (70.0%) of cis-4-amino-5-chloro-N-[1-[3-(3-ethyl-2-oxo-1-imidazolidinyl)propyl]-3-methoxy-4-piperidinyl]-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxamide ethanedioate(1:1); mp. 208.0 °C (comp. 121).

5 Example 10

A mixture of 2.6 parts of 2-iodomethyl-1,3-dioxolane, 3.3 parts of intermediate 2, 2.12 parts of sodium carbonate and 47 parts of N,N-dimethylformamide was stirred for 3 days at 70 °C. After cooling, the reaction mixture was evaporated. The residue was partitioned between dichloromethane and water. The organic layer was separated, washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile (to which a few drops of water were added). The product was filtered off at 0 °C and was dried in vacuo at 40 °C, yielding 2.3 parts (55.8%) of cis-4-amino-5-chloro-N-[1-(1,3-dioxolan-2-yl-methyl)-3-methoxy-4-piperidinyl]-2,3-dihydro-7-benzofurancarboxamide; mp. 149.1 °C (comp. 83).

Example 11

A mixture of 2.78 parts of 1-(3-chloropropyl)-2-methyl-1H-benzimidazole, 3.3 parts of intermediate 2, 2.04 parts of N,N-diethylethanamine and 94 parts of N,N-dimethylformamide was stirred for 20 hours at 70 °C. The reaction mixture was evaporated and water was added to the residue. The product was extracted with dichloromethane (2x) and the combined extracts were washed with water, dried, filtered and evaporated. The residue was crystallized from acetonitrile (to which a few drops of water were added), yielding 2.30 parts (44.6%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[3-(2-methyl-1H-benzimidazol-1-yl)-propyl]-4-piperidinyl]-7-benzofurancarboxamide monohydrate; mp. 151.5 °C (comp. 27).

Example 12

A mixture of 3.3 parts of intermediate 2, 4.4 parts of ethyl N-(2-oxoethyl)-N-phenylcarbamate, 2 parts of a solution of thiophene in methanol 4% and 198 parts of methanol was hydrogenated at normal pressure and 50 °C with 2 parts of platinum-on-charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was diluted with water and the product was extracted with dichloromethane (2x). The combined extracts were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 3.08 parts (58.6%) of ethyl cis-N-[2-[4-[[4-amino-5-chloro-2,3-dihydro-7-benzofuranyl]carbonyl]amino]-3-methoxy-1-piperidinyl]ethyl]-N-phenylcarbamate hemihydrate; mp. 116.4 °C (comp. 57).

40 Example 13

To a stirred mixture of 3.4 parts of intermediate 7, 2 parts of tetrahydrofuran, 2 parts of a solution of thiophene in methanol 4% and 119 parts of methanol was added dropwise a mixture of 11 ml of an acetaldehyde solution in tetrahydrofuran 10% and 8.9 parts of tetrahydrofuran, during the hydrogenation. After completion of the hydrogenation, the catalyst was filtered off and the filtrate was evaporated. The residue was dissolved in dichloromethane and this solution was washed with water (2x), dried, filtered and evaporated. The residue was recrystallized from acetonitrile. The product was filtered off and dried, yielding 2.66 parts (72.3%) of cis-5-amino-6-chloro-N-(1-ethyl-3-methoxy-4-piperidinyl)-3,4-dihydro-2H-1-benzopyran-8-carboxamide; mp. 153.8 °C (comp. 81).

50

Example 14

A mixture of 3 parts of 1-hexanal, 3.7 parts of intermediate 3, 1 part of a solution of thiophene in methanol 4% and 242.5 parts of 2-methoxyethanol was hydrogenated at normal pressure and at 50 °C with 2 parts of platinum-on-charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH (NH₃) 98:2). The eluent of the desired fraction was evaporated and the residue was crystallized from 2,2'-oxybispropane. The product was dried in vacuo at 70 °C, yielding 3.20 parts (68.5%)

of cis-4-amino-5-chloro-N-(1-hexyl-3-hydroxy-4-piperidiny)-2,3-dihydro-7-benzofurancarboxamide; mp. 130.4 °C (comp. 8).

Example 15

5 A mixture of 4.5 parts of (1,1-dimethylethyl) (2-oxoethyl)methylcarbamate, 5.5 parts of intermediate 2, 1 part of a solution of thiophene in methanol 4%, 198 parts of methanol and 2 parts of potassium acetate was hydrogenated at normal pressure and room temperature with 2 parts of palladium-on-charcoal catalyst 10%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was
10 evaporated. The residue was partitioned between trichloromethane and water. The organic layer was separated, washed with water, dried, filtered and evaporated. The residue was solidified in 2,2'-oxybispropane (to which a few drops of water were added). The product was filtered off at 0 °C and dried in vacuo at 40 °C, yielding 6.3 parts (76.7%) of (1,1-dimethylethyl) cis-[2-[4-[(4-amino-5-chloro-2,3-dihydro-7-benzofuranyl)carbonylamino]-3-methoxy-1-piperidiny]ethyl]methylcarbamate (comp. 41).

Example 16

To a refluxing solution of 17.4 parts of intermediate 2 in 195 parts of 2-propanol were added 4.03 parts of 2-propenenitrile. Stirring at reflux temperature was continued for 18 hours. The reaction mixture was
20 evaporated and the residue was crystallized from 2-propanol. The product was filtered off and dried in vacuo at 60 °C, yielding 14.8 parts (73.7%) of cis-4-amino-5-chloro-N-[1-(2-cyanoethyl)-3-methoxy-4-piperidiny]-2,3-dihydro-7-benzofurancarboxamide; mp. 190.7 °C (comp. 97).

Example 17

25 A solution of 15.7 parts of cis-4-amino-5-chloro-N-[1-(cyanomethyl)-3-methoxy-4-piperidiny]-2,3-dihydro-7-benzofurancarboxamide in 178 parts of tetrahydrofuran and 158 parts of methanol was hydrogenated at normal pressure and at room temperature with 6 parts of Raney nickel. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was
30 purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH(NH₃) 93:7). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile (to which a few drops of water were added). The product was filtered off at 0 °C and dried in vacuo at 40 °C, yielding 8.5 parts (53.6%) of cis-4-amino-N-[1-(2-aminoethyl)-3-methoxy-4-piperidiny]-5-chloro-2,3-dihydro-7-benzofurancarboxamide (comp. 35).

Example 18

To a cooled (ice-bath) mixture of 3.8 parts of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-(methylamino)ethyl]-4-piperidiny]-7-benzofurancarboxamide monohydrate in 104.3 parts of trichloromethane
40 were added 1.3 parts of 1-pyrrolidinecarbonyl chloride. After stirring for 15 min. at 0 °C, there were added dropwise 1.31 parts of N,N-diethylethanamine, keeping the temperature below 10 °C. Stirring was continued for 20 hours at room temperature. The reaction mixture was washed with water, dried, filtered and evaporated. The residue was crystallized from acetonitrile (to which some water was added). The product was filtered off at 0 °C and dried in vacuo at 40 °C, yielding 3.3 parts (73.6%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-[methyl(1-pyrrolidinylcarbonyl)amino]ethyl]-4-piperidiny]-7-benzofurancarboxamide monohydrate; mp. 112.0 °C (comp. 43).

Example 19

50 A mixture of 1.4 parts of 2-chloro-3-pyridinecarbonitrile, 3.2 parts of cis-4-amino-N-[1-(4-aminobutyl)-3-methoxy-4-piperidiny]-5-chloro-2,3-dihydro-7-benzofurancarboxamide, 65.8 parts of N,N-dimethylformamide and 1.3 parts of sodium carbonate was stirred for 20 hours at 70 °C. The solvent was evaporated and the residue was dissolved in trichloromethane. The organic layer was washed with water, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CHCl₃/CH₃OH (NH₃) 98:2). The
55 eluent of the desired fraction was evaporated and the residue was crystallized from 2,2'-oxybispropane. The product was dried in vacuo at 60 °C, yielding 1.44 parts (35.4%) of cis-4-amino-5-chloro-N-[1-[4-[(3-cyano-2-pyridinyl)amino]butyl]-3-methoxy-4-piperidiny]-2,3-dihydro-7-benzofurancarboxamide hemihydrate; mp. 129.7 °C (comp. 6).

Example 20

A mixture of 1.18 parts of 2-chloro-4(3H-quinazolinone, 2.40 parts of compound 35 and a minimal amount of N,N-dimethylformamide was stirred for 3 hours at 120 °C. After cooling, the reaction mixture was partitioned
 5 between dichloromethane and methanol. The organic layer was separated, dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH 90:10). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile (to which some water was added). The product was filtered off at 0 °C and dried, yielding 0.95 parts (37.5%) of cis-4-amino-5-chloro-2,3-dihydro-N-[1-[2-(3,4-dihydro-4-oxo-2-quinazolinyl)amino]ethyl]-3-methoxy-4-piperidinyl]-7-benzofurancarboxamide sesquihydrate; mp. 191.8 °C (comp. 88).
 10

Example 21

A mixture of 4.69 parts of cis-4-amino-N-[1-(2-aminoethyl)-3-methoxy-4-piperidinyl]-5-chloro-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxamide dihydrochloride, 1.54 parts of 2-chloro-3-methylpyridazine and 1.68 parts of calciumoxide was stirred for 20 hours at 120 °C. After cooling, the reaction mixture was diluted with water and the product was extracted with dichloromethane (3x). The combined extracts were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH(NH₃) 95:5). The eluent of the desired fraction was evaporated and the residue was converted into the
 20 ethanedioate salt in 2-propanol. The product was filtered off and dried, yielding 1.38 parts (23.1%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-[(3-methyl-2-pyrazinyl)amino]ethyl]-4-piperidinyl]-2,2-dimethyl-7-benzofurancarboxamide ethanedioate (1:1) monohydrate; mp. 117.1 °C (comp. 130).

Example 22

A mixture of 5 parts of cis-5-amino-N-[1-(3-aminopropyl)-3-methoxy-4-piperidinyl]-6-chloro-3,4-dihydro-2H-1-benzopyran-8-carboxamide, 3.2 parts of 2-methylthio-4-pyrimidinol and 79 parts of acetonitrile was stirred over weekend at reflux temperature. The reaction mixture was evaporated and the residue was partitioned between dichloromethane and ammonia (aq.). The aqueous layer was separated and re-extracted with
 30 dichloromethane (2x). The combined dichloromethane layers were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CH₂Cl₂/CH₃OH(NH₃) 95:5). The eluent of the two desired fractions was evaporated and the residues were separately crystallized from acetonitrile. The product was filtered off and dried in vacuo at 70 °C, yielding a first fraction of 2.22 parts (35.2%) of cis-5-amino-6-chloro-3,4-dihydro-N-[1-[3-[(4-hydroxy-2-pyrimidinyl)amino]propyl]-3-methoxy-4-piperidinyl]-2H-1-benzopyran-8-carboxamide hemihydrate; mp. 142.6 °C and a second fraction of 1.00 part (15.9%) of cis-5-amino-6-chloro-3,4-dihydro-N-[1-[3-[(4-hydroxy-2-pyrimidinyl)amino]propyl]-3-methoxy-4-piperidinyl]-2H-1-benzopyran-8-carboxamide hemihydrate; mp. 143.5 °C. Total yield: 3.22 parts (51.1%) of product (comp. 128).
 35

Example 23

A mixture of 5.4 parts of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[3-(2-methyl-1,3-dioxolan-2-yl)propyl]-4-piperidinyl]-2,2-dimethyl-7-benzofurancarboxamide and 85 ml of an aqueous sulfuric acid solution 1% was stirred for 2 hours at reflux temperature. After cooling, the reaction mixture was basified with
 45 ammonia and extracted with dichloromethane (2x). The combined extracts were dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CH₂Cl₂/CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was suspended in 2,2'-oxybispropane. The product was filtered off and dried, yielding 2.4 parts (51.6%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-(4-oxopentyl)-4-piperidinyl]-2,2-dimethyl-7-benzofurancarboxamide hemihydrate; mp. 137.7 °C (comp. 112).
 50


Example 24

A mixture of 6.3 parts of compound 41, 23.4 parts of 2-propanol, saturated with hydrochloric acid and 198 parts of methanol was stirred for 15 min. at reflux temperature. After cooling, the reaction mixture was evaporated. The residue was taken up in water and the whole was basified with ammonia. The product was extracted with trichloromethane and the extract was dried, filtered and evaporated. The residue was crystallized from acetonitrile (to which a few drops of water were added). The product was filtered off at








0°C and dried in vacuo at 40°C, yielding 3.8 parts (72.9%) of cis-4-amino-5-chloro-2,3-dihydro-N-[3-methoxy-1-[2-(methylamino)ethyl]-4-piperidinyl]-7-benzofurancarboxamide monohydrate (comp. 42).










The compounds listed in Table 2 were prepared according to similar procedures as described in any of the proceeding examples 5-24.









Table 2


















Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
1	5		2	-CH ₃	-O-(CH ₂) ₂ -		173.7







Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
2	5		2	-CH ₃	-O-(CH ₂) ₂ -		171.0
3	11	4-F-C ₆ H ₄ -O-	3	-CH ₃	-O-(CH ₂) ₂ -		138.6
4	11	CN-	3	-CH ₃	-O-(CH ₂) ₂ -		-
5	17	H ₂ N-	4	-CH ₃	-O-(CH ₂) ₂ -		-
6	19	3-cyano-2-pyridyl-NH-	4	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	129.7
7	5		2	-H	-O-(CH ₂) ₂ -		209.9
8	14	H-	6	-H	-O-(CH ₂) ₂ -		130.4
9	9	2-pyridyl-	1	-H	-O-(CH ₂) ₂ -		159.4
10	9	2-pyridyl-	1	-CH ₃	-O-(CH ₂) ₂ -		150.4
11	5	1-pyrrolidinyl-C(O)-	3	-CH ₃	-O-(CH ₂) ₂ -		183.7
12	8	tetrahydro-2-furanyl-	1	-CH ₃	-O-(CH ₂) ₂ -		172.2
13	5		3	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	134.3
14	14	H-	6	-CH ₃	-O-(CH ₂) ₂ -		129.8
15	5		2	-CH ₃	-O-(CH ₂) ₂ -		161.8
16	5		2	-CH ₃	-O-(CH ₂) ₂ -		123
17	11		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	124
18	5	2-CH ₃ -1,3-dioxolan-2-yl	3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	118.7
19	23	CH ₃ -C(O)-	3	-CH ₃	-O-(CH ₂) ₂ -		129.8
20	11	c.C ₆ H ₁₁ -	2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	117.3
21	13	H-	2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	134.7
22	5		2	-CH ₃	-O-(CH ₂) ₂ -		266.0









Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
23	5		3	-CH ₃	-O-(CH ₂) ₂ -		124.2
24	11	H ₅ C ₂ -O-C(O)-	3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	92.8
25	5		3	-H	-O-(CH ₂) ₂ -		177.2
26	5		3	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	128.0
27	11		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	151.5
28	11		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	147.9
29	5		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	124.3
30	6		2	-CH ₃	-O-(CH ₂) ₂ -		274.9
31	11		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	111.9
32	5		2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	157.3










Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
33	5		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	129.9
34	11	NC-	1	-CH ₃	-O-(CH ₂) ₂ -		
35	17	H ₂ N-	2	-CH ₃	-O-(CH ₂) ₂ -		
36	18	H ₅ C ₂ -O-C(O)-NH-	2	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	145.2
37	18	(H ₇ C ₃) ₂ -N-C(O)-NH-	2	-CH ₃	-O-(CH ₂) ₂ -		157.4
38	7		3	-CH ₃	-O-(CH ₂) ₂ -O-		157.8
39	8	tetrahydro-2-furanyl-	1	-CH ₃	-O-(CH ₂) ₂ -O-		191.6
40	18		2	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	145.4
41	15		2	-CH ₃	-O-(CH ₂) ₂ -		
42	24	CH ₃ -NH-	2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	
43	18		2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	112.0
44	9		3	-CH ₃	-O-(CH ₂) ₂ -		203.6
45	5		4	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	113.2
46	9		3	-CH ₃	-O-(CH ₂) ₂ -		180.2







Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
47	11		2	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	202.6
48	15	H-	6	-CH ₃	-O-(CH ₂) ₂ -O-		129.7
49	7		2	-CH ₃	-O-(CH ₂) ₂ -O-		171.9
50	11	4-F-C ₆ H ₄ -O-	3	-CH ₃	-O-(CH ₂) ₂ -O-		142.3
51	8		1	-CH ₃	-O-(CH ₂) ₂ -		239.2
52	12	2-furanyl-	1	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	87.0
53	12		1	-CH ₃	-O-(CH ₂) ₂ -		191.1
54	8	tetrahydro-2-furanyl-	2	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	124.6
55	8	tetrahydro-2-pyranyl-	1	-CH ₃	-O-(CH ₂) ₂ -		150.8
56	8	tetrahydro-2-furanyl-	1	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		170.1
57	12		2	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	116.4
58	11		3	-CH ₃	-O-(CH ₂) ₂ -	HCl	231.9
59	11	CH ₃ -O-	3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	118.3
60	7		3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		187.1
61	7		3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	103.0
62	5		3	-H	-O-(CH ₂) ₂ -		216.9

Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
63	8	tetrahydro-2-furanyl-	2	-H	-O-(CH ₂) ₂ -		154.8
64	13	H-	2	-H	-O-(CH ₂) ₂ -		171.5
65	8	tetrahydro-2-furanyl-	1	-H	-O-(CH ₂) ₂ -		186.4
66	11	HC(O)-NH-	4	-CH ₃	-O-(CH ₂) ₂ -		189.9
67	11		3	-CH ₃	-O-(CH ₂) ₂ -		166.1
68	8	tetrahydro-2-furanyl-	3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	118.0
69	11		3	-CH ₃	-O-(CH ₂) ₂ -		146.6
70	11		3	-CH ₃	-O-(CH ₂) ₂ -	3/2 H ₂ O	130.0
71	5		3	-CH ₃	-O-CH(CH ₃)-CH ₂ -	1/2 H ₂ O	94.2
72	8	tetrahydro-2-furanyl-	1	-CH ₃	-O-CH(CH ₃)-CH ₂ -	1/2 H ₂ O	67.6
73	8	tetrahydro-2-furanyl-	4	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	153.4
74	12	C ₆ H ₅ -	1	-CH ₃	-O-(CH ₂) ₂ -		129.7
75	11	H ₂ C=CH-	1	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	142.3
76	8	tetrahydro-2-furanyl-	1	-CH ₃	-O-(CH ₂) ₃ -		158.1
77	11	c.C ₃ H ₅ -	1	-CH ₃	-O-(CH ₂) ₂ -		162.3
78	11	(CH ₃) ₂ CH-O-	2	-CH ₃	-O-(CH ₂) ₂ -		121.9
79	7		3	-CH ₃	-O-(CH ₂) ₃ -		100.6
80	6		2	-CH ₃	-O-(CH ₂) ₂ -		260.8
81	13	H-	2	-CH ₃	-O-(CH ₂) ₃ -		153.8
82	11	(CH ₃) ₂ CH-O-	3	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	93.2

Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
83	10	1,3-dioxolanyl-	1	-CH ₃	-O-(CH ₂) ₂ -		149.1
84	12	H-	1	-CH ₃	-O-(CH ₂) ₂ -		214.6
85	12	c.C ₆ H ₁₁ -	0	-CH ₃	-O-(CH ₂) ₂ -	H ₂ O	139.3
86	5		3	-CH ₃	-O-(CH ₂) ₂ -		264.2
87	11	(CH ₃) ₂ CH-O-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	HCl/H ₂ O	151.0
88	20		2	-CH ₃	-O-(CH ₂) ₂ -	3/2 H ₂ O	191.8
89	9	2-CH ₃ -1,3-dioxolan-2-yl-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂	135.1
90	11		3	-CH ₃	-O-(CH ₂) ₂ -		210.7
91	11	2-pyridyl-	1	-CH ₃	-O-(CH ₂) ₃ -	H ₂ O	96.2
92	5		2	-CH ₃	-O-(CH ₂) ₂ -	3/2 H ₂ O	271.7
93	5		2	-CH ₃	-O-(CH ₂) ₂ -		230.5
94	13	H-	2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		174.4
95	11	4-F-C ₆ H ₄ -O-	3	-CH ₃	-O-(CH ₂) ₃ -		134.2
96	7		2	-CH ₃	-O-(CH ₂) ₃ -		219.1
97	16	NC-	2	-CH ₃	-O-(CH ₂) ₂ -		
98	17	H ₂ N-	3	-CH ₃	-O-(CH ₂) ₂ -		185.9
99	11	(CH ₃) ₂ CH-O-	2	-CH ₃	-O-(CH ₂) ₃ -		141.4
100	11	NC-	1	-CH ₃	-O-(CH ₂) ₃ -		175
101	17	H ₂ N-	2	-CH ₃	-O-(CH ₂) ₃ -		138.5

Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
102	22		3	-CH ₃	-O-(CH ₂) ₂ -	1/2 H ₂ O	188.6
103	11	(CH ₃) ₂ CH-O-	3	-CH ₃	-O-(CH ₂) ₃ -	HCl/H ₂ O	200
104	21		2	-CH ₃	-O-(CH ₂) ₃ -		200.2
105	16	NC-	2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		
106	17	H ₂ N-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	2(COOH) ₂	
107	22		3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		163.8
108	16	NC-	1	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		183.3
109	11	2-CH ₃ -1,3-dioxolan-2-yl-	3	-CH ₃	-O-(CH ₂) ₃ -		127.8
110	23	CH ₃ -C(O)-	3	-CH ₃	-O-(CH ₂) ₃ -	(COOH) ₂	168.4
111	9	4-F-C ₆ H ₄ -O-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂	140.3
112	23	CH ₃ -C(O)-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	1/2 H ₂ O	137.7
113	12	4-F-C ₆ H ₄ -	1	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		186.7
114	11		3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂ 1/2 H ₂ O	185.1
115	5		2	-CH ₃	-O-(CH ₂) ₃ -	H ₂ O	111.5
116	10	1,3-dioxolanyl-	1	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂	184.9
117	7		3	-CH ₃	-O-(CH ₂) ₃ -		165.2
118	7		2	-CH ₃	-O-(CH ₂) ₃ -		170.9
119	8	c.C ₆ H ₁₁ -O-	3	-CH ₃	-O-(CH ₂) ₃ -		136.4
120	8	c.C ₆ H ₁₁ -O-	3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂	173.0
121	9		3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂	208.0


Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
122	16	NC-	2	-CH ₃	-O-(CH ₂) ₃ -		
123	17	H ₂ N-	3	-CH ₃	-O-(CH ₂) ₃ -		159.6
124	11		3	-CH ₃	-O-(CH ₂) ₃ -		208.6
125	18	CH ₃ -C(O)-NH-	3	-CH ₃	-O-(CH ₂) ₃ -		182.3
126	21		3	-CH ₃	-O-(CH ₂) ₃ -	H ₂ O	131.4
127	7		2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	H ₂ O	159.5
128	22		3	-CH ₃	-O-(CH ₂) ₃ -	1/2 H ₂ O	143.5
129	17	H ₂ N-	2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	2 HCl	
130	21		2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂ H ₂ O	117.1
131	5		2	-CH ₃	-O-(CH ₂) ₃ -		158.2
132	5		2	-CH ₃	-O-(CH ₂) ₃ -		195.6
133	11		3	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -	2(COOH) ₂ 1/2 H ₂ O	186.4
134	12	H-	1	-CH ₃	-O-(CH ₂) ₃ -		184.9
135	7		2	-CH ₃	-O-C(CH ₃) ₂ -CH ₂ -		183.4













Comp. no.	Ex. no.	L ²	n	R ³	-O-A-	base/salt form	mp. (°C)
136	7		3	-CH ₃	-O-(CH ₂) ₃ -		149.5
137	11		3	-CH ₃	-O-(CH ₂) ₃ -		134.1
138	11		3	-CH ₃	-O-(CH ₂) ₃ -	(COOH) ₂	223.6
139	12	H-	1	-CH ₃	O-C(CH ₃) ₂ -CH ₂ -	(COOH) ₂ 1/2 H ₂ O	215.2
140	21		3	-CH ₃	O-C(CH ₃) ₂ -CH ₂ -	1/2 H ₂ O	185.6
141	5		2	-CH ₃	O-C(CH ₃) ₂ -CH ₂ -		122.6
142	21		3	-CH ₃	-O-(CH ₂) ₃ -	1/2 H ₂ O	164.2


Example 25

The compounds listed in Table 3 are prepared according to similar procedures as described in any of the proceeding examples.

Table 3



Comp. no.	L ²	n	R ³	-O-A-
143		0	-CH ₃	-O-(CH ₂) ₂ -
144		3	CH ₃	-O-(CH ₂) ₂ -
145		3	CH ₃	-O-(CH ₂) ₂ -
146		3	CH ₃	-O-(CH ₂) ₂ -
147		2	CH ₃	-O-(CH ₂) ₂ -
148		2	CH ₃	-O-(CH ₂) ₂ -
149		2	CH ₃	-O-(CH ₂) ₂ -
150		1	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₂ -
151	4-F-C ₆ H ₄ -O-	3	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₂ -
152		2	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₂ -
153	(CH ₃) ₂ CH-O-	3	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₂ -
154		1	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₃ -
155	4-F-C ₆ H ₄ -O-	3	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₃ -
156		2	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₃ -
157	(CH ₃) ₂ CH-O-	3	CH ₃	-O-C(CH ₃) ₂ -(CH ₂) ₃ -
158		1	CH ₃	-O-(CH ₂) ₄ -
159	4-F-C ₆ H ₄ -O-	3	CH ₃	-O-(CH ₂) ₄ -

Comp. no.	L ²	n	R ³	-O-A-
160		2	CH ₃	-O-(CH ₂) ₄ -
161	(CH ₃) ₂ CH-O-	3	CH ₃	-O-(CH ₂) ₄ -

C. Pharmacological examples

The useful gastrointestinal motility stimulating properties of the compounds of the present invention and in particular their capability to enhance the contractility of the colon can be demonstrated in the following test.

Example 26

Colon ascendens induced contractions.

The experiment was conducted according to similar procedures as described in The Journal of Pharmacology and Experimental Therapeutics, 234, 776-783 (1985). Colon segments, 4.5 cm long, were vertically suspended with a preload of 2 g in 100 ml of a De Jalon solution [KCl 5.6 mM; CaCl₂·2H₂O 0.54 mM; NaHCO₃ 5.9 mM; NaCl 154.1 mM; glucose 2.8 mM] by 37.5 °C and gassed with a mixture of 95% O₂ and 5% CO₂. Contractions were measured isotonicly with a HP 7 DCDT- 1000, JSID Displacement Transducer Control Unit.

After a stabilization period of about 20 minutes, 3.4x10⁻⁶ M methacholine was given at a time interval of 15 minutes. When reproducible contractions were obtained, the test compound was administered to the bathing solution. The compound effect was followed for 10 minutes and expressed relative to the maximal concentrations induced by 3.4x10⁻⁶ M methacholine. The % effect for a representative number of compounds of formula (I) is depicted hereunder in Table 4.

Table 4

	Comp. No.	Dose 1.10^{-6} M	Dose 1.10^{-7} M
5	1	+ 48%	+ 42%
	2	+ 32%	+ 31%
	3	+ 49%	+ 39%
	5	+ 34%	+ 31%
	8	+ 45%	+ 27%
10	11	+ 30%	+ 26%
	13	+ 43%	+ 40%
	14	+ 52%	+ 41%
	26	+ 47%	+ 37%
	33	+ 34%	+ 25%
15	38	+ 33%	+ 27%
	40	+ 22%	+ 32%
	43	+ 36%	+ 20%
	46	+ 26%	+ 30%
	47	+ 28%	+ 25%
20	48	+ 37%	+ 29%
	53	+ 30%	+ 28%
	57	+ 27%	+ 25%
	66	+ 28%	+ 21%
	68	+ 41%	+ 26%
25	69	+ 24%	+ 29%
	70	+ 31%	+ 24%
	73	+ 27%	+ 24%
	76	+ 24%	+ 20%
	79	+ 29%	+ 36%
30	80	+ 36%	+ 23%
	86	+ 29%	+ 24%
	95	+ 35%	+ 24%
	96	+ 34%	+ 26%
	118	+ 25%	+ 29%
35	132	+ 44%	+ 29%

D. Composition Examples

Example 27: ORAL DROPS

500 Parts of the A.I. was dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60–80 °C. After cooling to 30–40 °C there were added 35 l of polyethylene glycol and the mixture was stirred well. Then there was added a solution of 1750 parts of sodium saccharin in 2.5 l of purified water and while stirring there were added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 10 mg/ml of A.I.. The resulting solution was filled into suitable containers.

Example 28: ORAL SOLUTION

9 Parts of methyl 4-hydroxybenzoate and 1 part of propyl 4-hydroxybenzoate were dissolved in 4 l of boiling purified water. In 3 l of this solution were dissolved first 10 parts of 2,3-dihydroxybutanedioic acid and thereafter 20 parts of the A.I. The latter solution was combined with the remaining part of the former solution and 121 1,2,3-propanetriol and 3 l of sorbitol 70% solution were added thereto. 40 Parts of sodium saccharin were dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence were added. The latter solution was combined with the former, water was added q.s. to a volume of 20 l providing an oral solution comprising 5 mg of the active ingredient per teaspoonful (5 ml). The resulting solution was filled in suitable containers.

Example 29 : CAPSULES

20 Parts of the A.I., 6 parts sodium lauryl sulfate, 56 parts starch, 56 parts lactose, 0.8 parts colloidal silicon dioxide, and 1.2 parts magnesium stearate were vigorously stirred together. The resulting mixture was subsequently filled into 1000 suitable hardened gelatin capsules, comprising each 20 mg of the active ingredient.

Example 30: FILM-COATED TABLETS10 Preparation of tablet core

A mixture of 100 parts of the A.I., 570 parts lactose and 200 parts starch was mixed well and thereafter humidified with a solution of 5 parts sodium dodecyl sulfate and 10 parts polyvinylpyrrolidone (Kollidon-K 90 ®) in about 200 ml of water. The wet powder mixture was sieved, dried and sieved again. Then there was added 100 parts microcrystalline cellulose (Avicel ®) and 15 parts hydrogenated vegetable oil (Sterotex ®). The whole was mixed well and compressed into tablets, giving 10.000 tablets, each containing 10 mg of the active ingredient.

Coating

20

To a solution of 10 parts methyl cellulose (Methocel 60 HG®) in 75 ml of denaturated ethanol there was added a solution of 5 parts of ethyl cellulose (Ethocel 22 cps ®) in 150 ml of dichloromethane. Then there were added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 Parts of polyethylene glycol was molten and dissolved in 75 ml of dichloromethane. The latter solution was added to the former and then there were added 2.5 parts of magnesium octadecanoate, 5 parts of polyvinylpyrrolidone and 30 ml of concentrated colour suspension (Opaspray K-1-2109®) and the whole was homogenated. The tablet cores were coated with the thus obtained mixture in a coating apparatus.

Example 31: INJECTABLE SOLUTION

30

1.8 Parts methyl 4-hydroxybenzoate and 0.2 parts propyl 4-hydroxybenzoate were dissolved in about 0.5 l of boiling water for injection. After cooling to about 50 °C there were added while stirring 4 parts lactic acid, 0.05 parts propylene glycol and 4 parts of the A.I.. The solution was cooled to room temperature and supplemented with water for injection q.s. ad 1 l, giving a solution comprising 4 mg/ml of A.I.. The solution was sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.

Example 32: SUPPOSITORIES

3 Parts A.I. was dissolved in a solution of 3 parts 2,3-dihydroxybutanedioic acid in 25 ml polyethylene glycol 400. 12 Parts surfactant (SPAN®) and triglycerides (Witepsol 555 ®) q.s. ad 300 parts were molten together. The latter mixture was mixed well with the former solution. The thus obtained mixture was poured into moulds at a temperature of 37-38 °C to form 100 suppositories each containing 30 mg/ml of the A.I.

Example 33: INJECTABLE SOLUTION

45

60 Parts of A.I. and 12 parts of benzylalcohol were mixed well and sesame oil was added q.s. ad 1 l, giving a solution comprising 60 mg/ml of A.I.. The solution was sterilized and filled in sterile containers.


50

55

Claims

Claims for the following Contracting States : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. A chemical compound of formula



a N-oxide form, a therapeutically active non-toxic addition salt or a stereochemically isomeric form thereof, wherein:

A is a radical of formula

-CH₂-CH₂- (a-1),

-CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5),

or

-CH₂-CH₂-CH₂-O- (a-6),

wherein one or two hydrogen atoms in said radicals (a-1) to (a-6) may be replaced by a C₁₋₆ alkyl radical;

R¹ is hydrogen or halo;

R² is amino, mono or di(C₁₋₆ alkyl)amino, arylC₁₋₆ alkylamino or C₁₋₆ alkylcarbonylamino;

R³ and R⁴ are each independently hydrogen or C₁₋₆ alkyl;

L is C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, C₃₋₆ alkenyl optionally substituted with aryl, or L is a radical of formula

-Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

-Alk-Y-C(=O)-R⁸ (b-3),

or

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4),

wherein each Alk is C₁₋₆ alkanediyl; and

R⁵ is hydrogen, cyano, C₁₋₆ alkylsulfonylamino, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, aryl, di(aryl)-methyl or Het;

R⁶ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or Het;

X is O, S, SO₂ or NR⁷; said R⁷ being hydrogen, C₁₋₆ alkyl or aryl;

R⁸ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl; arylC₁₋₆ alkyl di(aryl)methyl or C₁₋₆ alkyloxy;

Y is NR⁹ or a direct bond; said R⁹ being hydrogen, C₁₋₆ alkyl or aryl;

R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or arylC₁₋₆ alkyl, or R¹⁰

and R¹¹ combined with the nitrogen atom bearing R¹⁰ and R¹¹ may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C₁₋₆ alkyl, amino or mono or di(C₁₋₆ alkyl)amino, or said R¹⁰ and R¹¹ combined with the nitrogen bearing R¹⁰ and R¹¹ may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C₁₋₆ alkyl;

each aryl being unsubstituted phenyl or phenyl substituted with 1,2 or 3 substituents each independently selected from halo, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkyloxy, amino-sulfonyl, C₁₋₆ alkylcarbonyl, nitro, trifluoromethyl, amino or aminocarbonyl; and

each Het being a five- or six-membered heterocyclic ring containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that no more than 2 oxygen and/or sulfur atoms are present, said five- or six-membered ring being optionally condensed with a five- or six-membered carboxylic or heterocyclic ring also containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that the latter ring does not contain more than 2 oxygen and/or sulfur atoms and that the total number of heteroatoms in the bicyclic ring system is less than 6; when Het is a monocyclic ring system it may optionally be substituted with up to 4 substituents; when Het is a bicyclic ringsystem it may optionally be substituted with up to 6 substituents; said substituents being selected from the group consisting of halo, hydroxy, cyano, trifluoromethyl, C₁₋₆ alkyl, arylC₁₋₆ alkyl, aryl, C₁₋₆ alkyloxy, C₁₋₆ alkyloxyC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkylthio, mercapto, nitro, amino, mono and di(C₁₋₆ alkyl)amino, arylC₁₋₆ alkylamino, aminocarbonyl, mono and di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyloxycarbonyl, arylC₁₋₆ alkyloxycarbonyl, a bivalent radical =O and S; provided that when R⁶ is Het, Het is connected to X on a carbon atom.

2. A chemical compound according to claim 1 wherein R¹ is hydrogen or halo; R² is hydrogen or amino; R³ is hydrogen or C₁₋₄ alkyl; R⁴ is hydrogen;

L is a radical of formula (b-1) wherein R⁵ is hydrogen, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, aryl or Het; or

L is a radical of formula (b-2) wherein X is O, S or NH and R⁶ is hydrogen, C₁₋₄ alkyl, aryl or Het; or


L is a radical of formula (b-3) wherein Y is NH or a direct bond and R⁸ is hydrogen, C₁₋₄ alkyl, aryl or C₁₋₄ alkyloxy; or

L is a radical of formula (b-4) wherein Y is NH or a direct bond and R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₄ alkyl or aryl, or R¹⁰ and R¹¹ combined with the nitrogen bearing said R¹⁰ and R¹¹ may form a pyrrolidinyl or piperidinyl radical.

3. A chemical compound according to claim 2 wherein the substituents on the 3 and 4 position of the piperidine ring have the cis-configuration.


4. A chemical compound according to claim 1 wherein R¹ is halo, R² is amino, R³ is C₁₋₄ alkyl, R⁴ is hydrogen and A is a radical of formula (a-1) or (a-2) wherein the carbon atom adjacent to the oxygen atom is optionally substituted with one or two C₁₋₄ alkyl substituents, or A is a radical of formula (a-5).

5. A chemical compound according to claim 1 wherein Het is a cyclic ether or thioether ring system selected from the group consisting of



wherein each X¹ and X² each independently are O or S; m is 1 or 2; each R¹² is hydrogen, C₁₋₄ alkyl,

C_{1-4} alkyloxy C_{1-4} alkyl or hydroxy C_{1-4} alkyl and R^{13} is hydrogen, halo or C_{1-4} alkyl, or
 wherein Het is heterocyclic ring system selected from the group consisting of pyridinyl which is
 optionally substituted with one or two substituents each independently selected from halo, hydroxy,
 cyano, C_{1-6} alkyl, trifluoromethyl, C_{1-6} alkyloxy, aminocarbonyl, mono and di(C_{1-6} alkyl)-aminocarbonyl,
 5 amino, mono and di(C_{1-6} alkyl)amino and C_{1-6} alkyloxycarbonyl; pyrimidinyl which is optionally substi-
 tuted with one or two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl,
 C_{1-6} alkyloxy, amino and mono and di(C_{1-6} alkyl)amino; pyridazinyl which is optionally substituted with
 C_{1-6} alkyl or halo; pyrazinyl which is optionally substituted with one or two substituents each
 independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy, amino, mono- and di-
 10 (C_{1-6} alkyl)amino and C_{1-6} alkyloxycarbonyl; pyrrolyl which is optionally substituted with C_{1-6} alkyl;
 pyrazolyl which is optionally substituted with C_{1-6} alkyl; imidazolyl which is optionally substituted with
 C_{1-6} alkyl; triazolyl which is optionally substituted with C_{1-6} alkyl; quinolinyl optionally substituted with
 up to two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy,
 amino, mono and di(C_{1-6} alkyl)amino and trifluoromethyl; isoquinolinyl optionally substituted with up to
 15 two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy,
 amino, mono and di(C_{1-6} alkyl)amino and trifluoromethyl; quinoxalinyl optionally substituted with up to
 two substituents each independently selected from C_{1-6} alkyl, hydroxy, halo, cyano and C_{1-6} alkyloxy;
 quinazolinyl optionally substituted with C_{1-6} alkyl; benzimidazolyl optionally substituted with C_{1-6} alkyl;
 indolyl optionally substituted with C_{1-6} alkyl; 5,6,7,8-tetrahydroquinolinyl optionally substituted with up
 20 to two substituents each independently selected from halo, hydroxy, cyano, C_{1-6} alkyl, C_{1-6} alkyloxy,
 amino, mono- and di(C_{1-6} alkyl)amino and trifluoromethyl; 5,6,7,8-tetrahydroquinoxalinyl optionally sub-
 stituted with up to two substituents each independently selected from C_{1-6} alkyl, hydroxy, halo, cyano
 and C_{1-6} alkyloxy; thiazolyl optionally substituted with C_{1-6} alkyl; oxazolyl optionally substituted with C_{1-6}
 25 C_{1-6} alkyl; benzoxazolyl optionally substituted with C_{1-6} alkyl; benzothiazolyl optionally substituted with
 C_{1-6} alkyl; or
 wherein Het is monocyclic amide ring system selected from



wherein

X^3 is O or S;


R^{14} is hydrogen, C_{1-6} alkyl or aryl C_{1-6} alkyl;


R^{15} is hydrogen, halo, C_{1-6} alkyl or aryl;

G^1 is $-CH_2-CH_2-$, $-CH=CH-$, $-N=N-$, $-C(=O)-CH_2-$ or $-CH_2-CH_2-CH_2-$, wherein one or two hy-
 40 drogen atoms each independently may be replaced by C_{1-6} alkyl; and


G^2 is $-CH_2-CH_2-$, $-CH_2-N(R^{14})-$ or $-CH_2-CH_2-CH_2-$, wherein one or two hydrogen atoms each
 45 independently may be replaced by C_{1-6} alkyl.

wherein Het is bicyclic amide ring system selected from







(d-8)




(d-9)




(d-10)



(d-11)



(d-12)



(d-13)

wherein X^4 and X^5 each independently are O or S;

each R^{16} independently is hydrogen, C_1-6 alkyl or aryl C_1-6 alkyl;

each R^{17} independently is hydrogen, halo, C_1-6 alkyl or C_1-6 alkoxy; and


R^{18} is hydrogen, halo, C_1-6 alkyl or aryl;

wherein the radicals (d-5), (d-6), (d-7) and (d-8) may be connected to respectively Alk or X by replacing either a hydrogen or a radical R^{16} and R^{17} by a free bond;

G^3 is $-CH=CH-CH=CH-$, $-(CH_2)_4-$, $-S-(CH_2)_2-$, $-S-(CH_2)_3-$, $-S-CH=CH-$, $-CH=CH-O-$, $-NH-(CH_2)_2-$, $-NH-(CH_2)_3-$, $-NH-CH=CH-$, $-NH-N=CH-CH_2-$, $-NH-CH=N-$ or $-NH-N=CH-$;


G^4 is $-CH=CH-CH=CH-$, $-CH=CCl-CH=CH-$, $-CCl=CH-CH=CH-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ or $-CH=N-CH=N-$.

6. A compound having the formula




a N -oxide form, a therapeutically active non-toxic addition salt or a stereochemically isomeric form thereof, wherein A, R^1 , R^2 , R^3 and R^4 are as defined in claim 1.

7. A compound having the formula




a salt or a stereochemically isomeric form thereof, wherein A, R^1 and R^2 are as defined in claim 1; provided that the compound is other than 4-amino-5-chloro-2-methyl-2,3-dihydro-7-benzofurancarboxylic acid and 4-amino-2,3-dihydro-2,2-dimethyl-7-benzofurancarboxylic acid.


8. A compound according to claim 7 wherein R¹ is chloro and R² is amino.
9. A pharmaceutical composition comprising a pharmaceutical carrier and as active ingredient a therapeutically effective amount of a compound as claimed in any one of claims 1 to 6.
10. A method of preparing a pharmaceutical composition as claimed in claim 9, characterized in that a therapeutically effective amount of a compound as claimed in any of claims 1 to 6 is intimately mixed with a pharmaceutical carrier.
11. A compound as claimed in any one of claims 1 to 6 for use as a medicine.
12. A process for preparing a compound as claimed in any of claims 1 to 5, characterized by
 a) N-alkylating a piperidine of formula



wherein A, R¹, R², R³ and R⁴ are as defined in claim 1, with an intermediate of formula L-W (III) wherein W is a reactive leaving group, in a reaction inert solvent, optionally in the presence of a base and/or a iodide salt;
 b) reacting a piperidinamine of formula




wherein R³ and R⁴ are as defined in claim 1, with a carboxylic acid of formula




or a functional derivative thereof, wherein A, R¹ and R² are as defined in claim 1, in a reaction-inert solvent, optionally in the presence of a reagent capable of forming amides; or
 c) reductively N-alkylating a compound of formula HD (II) with a ketone or aldehyde of formula L' = O (VI), wherein L' = O is a compound of formula L-H wherein two geminal hydrogen atoms in said C₁₋₆ alkanediyl or C₃₋₆ cycloalkanediyl are replaced by = O, in a reaction-inert medium;
 or optionally converting the compounds of formula (I) into each other following art-known functional group transformation reactions, and, if desired, converting a compound of formula (I) into a therapeutically active non-toxic salts by treatment with an appropriate acid, or conversely, converting a salt form into a free base form with alkali; and/or preparing the N-oxide forms and the stereochemically isomeric forms thereof.

13. A process for preparing a compound of formula Het-X-Alk-D (I-b-2-b) according to claim 1 wherein Het, X and Alk are as defined in claim 1 and D represents the radical




wherein A, R¹, R², R³ and R⁴ are as defined in claim 1, characterized by reacting a reagent of formula Het-W¹ (VII) or Het-X-H (VIII) with a piperidine of formula HX-Alk-D (I-b-2-a) or W²-Alk-D (IX) respectively, wherein W¹ and W² are both reactive leaving groups in a reaction-inert solvent, thus yielding a compound of formula Het-X-Alk-D (I-b-2-b).

14. A process for preparing a compound of formula NC-CH₂-CH₂-D (I-c) according to claim 1 wherein D represents the radical




wherein A, R¹, R², R³ and R⁴ have the same meaning as in claim 1, characterized by alkylating a piperidine of formula H-D (II) with CH₂=CH-CN (XV) in a reaction inert solvent, thus yielding a compound of formula NC-CH₂-CH₂-D (I-c); and optionally reducing said compound to the corresponding amine in a hydrogen containing medium in the presence of a catalyst.


15. A process for preparing a compound as claimed in claim 6, characterized by reacting a piperidinamine of formula



wherein P¹ represents a protective group and R³ and R⁴ are as defined in claim 1, with a carboxylic acid of formula




or a functional derivative thereof wherein A, R¹ and R² are as defined in Claim 1, and subsequently removing the protective group P¹ in the thus obtained intermediate



10 following art-known procedures in a reaction-inert solvent, and, if desired, converting a compound of formula (I) into a therapeutically active non-toxic salts by treatment with an appropriate acid, or conversely, converting a salt form into a free base form with alkali; and/or preparing the N-oxide forms and the stereochemically isomeric forms thereof.

15 **Claims for the following Contracting States : ES, GR**

1. A process for preparing a compound of formula



30 a N-oxide form, a therapeutically active non-toxic addition salt or a stereochemically isomeric form thereof, wherein:

A is a radical of formula

-CH₂-CH₂- (a-1),

35 -CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

40 -CH₂-CH₂-O- (a-5),

or

45 -CH₂-CH₂-CH₂-O- (a-6),

wherein one or two hydrogen atoms in said radicals (a-1) to (a-6) may be replaced by a C₁₋₆alkyl radical;

R¹ is hydrogen or halo;

50 R² is amino, mono or di(C₁₋₆alkyl)amino, arylC₁₋₆alkylamino or C₁₋₆alkylcarbonylamino;

R³ and R⁴ are each independently hydrogen or C₁₋₆alkyl;

L is C₃₋₆cycloalkyl, C₅₋₆cycloalkanonyl, C₃₋₆alkenyl optionally substituted with aryl, or L is a radical of formula

55 -Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

-Alk-Y-C(=O)-R⁸ (b-3),

or

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4),

wherein each Alk is C₁₋₆ alkanediyl; and

R⁵ is hydrogen, cyano, C₁₋₆ alkylsulfonylamino, C₃₋₆ cycloalkyl, C₅₋₆ cycloalkanonyl, aryl, di(aryl)-methyl or Het;

R⁶ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or Het;

X is O, S, SO₂ or NR⁷; said R⁷ being hydrogen, C₁₋₆ alkyl or aryl;

R⁸ is hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl, arylC₁₋₆ alkyl, di(aryl)methyl or C₁₋₆ alkyloxy;

Y is NR⁹ or a direct bond; said R⁹ being hydrogen, C₁₋₆ alkyl or aryl;


R¹⁰ and R¹¹ each independently are hydrogen, C₁₋₆ alkyl, C₃₋₆ cycloalkyl, aryl or arylC₁₋₆ alkyl, or R¹⁰ and R¹¹ combined with the nitrogen atom bearing R¹⁰ and R¹¹ may form a pyrrolidinyl or piperidinyl ring both being optionally substituted with C₁₋₆ alkyl, amino or mono or di(C₁₋₆ alkyl)amino, or said R¹⁰ and R¹¹ combined with the nitrogen bearing R¹⁰ and R¹¹ may form a piperazinyl or 4-morpholinyl radical both being optionally substituted with C₁₋₆ alkyl;

each aryl being unsubstituted phenyl or phenyl substituted with 1,2 or 3 substituents each independently selected from halo, hydroxy, C₁₋₆ alkyl, C₁₋₆ alkyloxy, aminosulfonyl, C₁₋₆ alkylcarbonyl, nitro, trifluoromethyl, amino or aminocarbonyl; and

each Het being a five- or six-membered heterocyclic ring containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that no more than 2 oxygen and/or sulfur atoms are present, said five- or six-membered ring being optionally condensed with a five- or six-membered carboxylic or heterocyclic ring also containing 1,2,3 or 4 heteroatoms selected from oxygen, sulfur and nitrogen, provided that the latter ring does not contain more than 2 oxygen and/or sulfur atoms and that the total number of heteroatoms in the bicyclic ring system is less than 6; when Het is a monocyclic ring system it may optionally be substituted with up to 4 substituents; when Het is a bicyclic ringsystem it may optionally be substituted with up to 6 substituents; said substituents being selected from the group consisting of halo, hydroxy, cyano, trifluoromethyl, C₁₋₆ alkyl, arylC₁₋₆ alkyl, aryl, C₁₋₆ alkyloxy, C₁₋₆ alkyloxyC₁₋₆ alkyl, hydroxyC₁₋₆ alkyl, C₁₋₆ alkylthio, mercapto, nitro, amino, mono and di(C₁₋₆ alkyl)amino, arylC₁₋₆ alkylamino, aminocarbonyl, mono and di(C₁₋₆ alkyl)aminocarbonyl, C₁₋₆ alkyloxycarbonyl, arylC₁₋₆ alkyloxycarbonyl, a bivalent radical =O and =S; provided that when R⁶ is Het, Het is connected to X on a carbon atom;


characterized by

a) N-alkylating a piperidine of formula




wherein A, R¹, R², R³ and R⁴ are as defined in claim 1, with an intermediate of formula L-W (III) wherein W is a reactive leaving group, in a reaction inert solvent, optionally in the presence of a base and/or a iodide salt;

b) reacting a piperidinamine of formula



wherein R^3 and R^4 are as defined in claim 1, with a carboxylic acid of formula




or a functional derivative thereof, wherein A, R^1 and R^2 are as defined in claim 1, in a reaction-inert solvent, optionally in the presence of a reagent capable of forming amides; or

15 c) reductively \underline{N} -alkylating a compound of formula HD (II) with a ketone or aldehyde of formula $L'=O$ (VI), wherein $L'=O$ is a compound of formula L-H wherein two geminal hydrogen atoms in said C_{1-6} alkanediyl or C_{3-6} cycloalkanediyl are replaced by $=O$, in a reaction-inert medium;

or optionally converting the compounds of formula (I) into each other following art-known functional group transformation reactions, and, if desired, converting a compound of formula (I) into a therapeutically active non-toxic salts by treatment with an appropriate acid, or conversely, converting a salt form into a free base form with alkali; and/or preparing the \underline{N} -oxide forms and the stereochemically isomeric forms thereof.


2. A process for preparing a compound of formula Het-X-Alk-D (I-b-2-b) wherein Het, X and Alk are as defined in claim 1 and D represents the radical
- 25



wherein A, R^1 , R^2 , R^3 and R^4 are as defined in claim 1, characterized by reacting a reagent of formula Het- W^1 (VII) or Het-X-H (VIII) with a piperidine of formula HX-Alk-D (I-b-2-a) or W^2 -Alk-D (IX) respectively, wherein W^1 and W^2 are both reactive leaving groups in a reaction-inert solvent, thus yielding a compound of formula Het-X-Alk-D (I-b-2-b).

40


3. A process for preparing a compound of formula NC- CH_2 - CH_2 -D (I-c) wherein D represents the radical
- 45




wherein A, R^1 , R^2 , R^3 and R^4 have the same meaning as in claim 1, characterized by alkylating a piperidine of formula H-D (II) with $CH_2=CH-CN$ (XV) in a reaction inert solvent, thus yielding a compound of formula NC- CH_2 - CH_2 -D (I-c); and optionally reducing said compound to the corresponding amine in a hydrogen containing medium in the presence of a catalyst.

55


4. A process for preparing a compound




15 a N-oxide form, a therapeutically active non-toxic addition salt or a stereochemically isomeric form thereof, wherein A, R¹, R², R³ and R⁴ are as defined in claim 1, characterized by reacting a piperidinamine of formula



25 wherein P¹ represents a protective group and R³ and R⁴ are as defined in claim 1, with a carboxylic acid of formula



35 or a functional derivative thereof, and subsequently removing the protective group P¹ in the thus obtained intermediate




50 following art-known procedures in a reaction-inert solvent, and, if desired, converting a compound of formula (I) into a therapeutically active non-toxic salts by treatment with an appropriate acid, or conversely, converting a salt form into a free base form with alkali; and/or preparing the N-oxide forms and the stereochemically isomeric forms thereof.

55

Patentansprüche

Patentansprüche für folgende Vertragsstaaten: AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Chemische Verbindung mit der Formel



eine N-Oxidform, ein therapeutisch wirksames nicht-toxisches Additionssalz oder eine stereochemisch isomere Form hiervon, worin:

A für einen Rest der Formel

-CH₂-CH₂- (a-1),

-CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

-CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5)

oder

-CH₂-CH₂-CH₂-O- (a-6)

steht, worin ein oder zwei Wasserstoffatome in diesen Resten (a-1) bis (a-6) durch einen C₁₋₆-Alkylrest ersetzt sein können;

R¹ Wasserstoff oder Halogen bedeutet;

R² für Amino, Mono- oder Di(C₁₋₆-alkyl)amino, Aryl-C₁₋₆-alkylamino oder C₁₋₆-Alkylcarbonylamino steht;

R³ und R⁴ jeweils unabhängig Wasserstoff oder C₁₋₆-Alkyl bedeuten;

L für C₃₋₆-Cycloalkyl, C₅₋₆-Cycloalkanonyl, gegebenenfalls durch Aryl substituiertes C₃₋₆-Alkenyl steht oder L einen Rest der Formel

-Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

-Alk-Y-C(=O)-R⁸ (b-3)

oder

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4)

bedeutet, worin Alk jeweils C₁₋₆-Alkandiyl darstellt; und

R⁵ für Wasserstoff, Cyano, C₁₋₆-Alkylsulfonylamino, C₃₋₆-Cycloalkyl, C₅₋₆-Cycloalkanonyl, Aryl, Di(aryl)methyl oder Het steht;

R⁶ Wasserstoff, C₁₋₆-Alkyl, C₃₋₆-Cycloalkyl, Aryl oder Het bedeutet;

X für O, S, SO₂ oder NR⁷ steht; worin der genannte Rest R⁷ Wasserstoff, C₁₋₆-Alkyl oder Aryl darstellt;

R⁸ für Wasserstoff, C₁₋₆-Alkyl, C₃₋₆-Cycloalkyl, Aryl, Aryl-C₁₋₆-alkyl, Di(aryl)methyl oder C₁₋₆-Alkyloxy steht;

Y für NR⁹ oder eine direkte Bindung steht; welcher Rest R⁹ Wasserstoff, C₁₋₆-Alkyl oder Aryl darstellt;

5 R¹⁰ und R¹¹ jeweils unabhängig Wasserstoff, C₁₋₆-Alkyl, C₃₋₆-Cycloalkyl, Aryl oder Aryl-C₁₋₆-alkyl bedeuten, oder R¹⁰ und R¹¹ zusammen mit dem die Reste R¹⁰ und R¹¹ tragenden Stickstoffatom einen Pyrrolidiny- oder Piperidiny- oder Piperidiny- oder Piperidiny- ring bilden können, die beide gegebenenfalls durch C₁₋₆-Alkyl, Amino oder Mono- oder Di(C₁₋₆-alkyl)amino substituiert sein können, oder worin diese Reste R¹⁰ und R¹¹,
10 gemeinsam mit dem R¹⁰ und R¹¹ tragenden Stickstoffatom, einen Piperaziny- oder 4-Morpholinyrest bilden können, die beide gegebenenfalls durch C₁₋₆-Alkyl substituiert sind;

jedes Aryl unsubstituiertes Phenyl oder durch 1, 2 oder 3 Substituenten substituiertes Phenyl darstellt, welche Substituenten jeweils unabhängig unter Halogen, Hydroxy, C₁₋₆-Alkyl, C₁₋₆-Alkyloxy, Aminosulfonyl, C₁₋₆-Alkylcarbonyl, Nitro, Trifluormethyl, Amino oder Aminocarbonyl ausgewählt sind; und

15 jedes Het einen fünf- oder sechsgliedrigen heterocyclischen Ring mit einem Gehalt an 1, 2, 3 oder 4, unter Sauerstoff, Schwefel und Stickstoff ausgewählten Heteroatomen bedeutet, mit der Maßgabe, daß nicht mehr als 2 Sauerstoff- und/oder Schwefelatome vorliegen, wobei dieser fünf- oder sechsgliedrige Ring gegebenenfalls mit einem fünf- oder sechsgliedrigen carbocyclischen Ring oder heterocyclischen Ring, der ebenfalls 1, 2, 3 oder 4, unter Sauerstoff, Schwefel und Stickstoff ausgewählte Heteroatome enthält, kondensiert ist, mit der Maßgabe, daß der letztgenannte Ring nicht mehr als 2
20 Sauerstoff- und/oder Schwefelatome enthält und daß die Gesamtanzahl von Heteroatomen in dem bicyclischen Ringsystem kleiner als 6 ist; wobei dann, wenn Het ein monocyclisches Ringsystem bedeutet, dieses gegebenenfalls durch bis zu 4 Substituenten substituiert sein kann; und wenn Het ein bicyclisches Ringsystem darstellt, dieses gegebenenfalls durch bis zu 6 Substituenten substituiert sein
25 kann; welche Substituenten aus der aus Halogen, Hydroxy, Cyano, Trifluormethyl, C₁₋₆-Alkyl, Aryl-C₁₋₆-alkyl, Aryl, C₁₋₆-Alkyloxy, C₁₋₆-Alkyloxy-C₁₋₆-alkyl, Hydroxy-C₁₋₆-alkyl, C₁₋₆-Alkylthio, Mercapto, Nitro, Amino, Mono- und Di(C₁₋₆-alkyl)amino, Aryl-C₁₋₆-alkylamino, Aminocarbonyl, Mono- und Di-(C₁₋₆-alkyl)aminocarbonyl, C₁₋₆-Alkyloxycarbonyl, Aryl-C₁₋₆-alkyloxycarbonyl, einem zweiwertigen Rest = O und = S bestehenden Gruppe ausgewählt sind; mit der Maßgabe, daß dann, wenn R⁶ für Het
30 steht, Het an einem Kohlenstoffatom an X gebunden ist.

2. Chemische Verbindung nach Anspruch 1, worin R¹ für Wasserstoff oder Halogen steht; R² Wasserstoff oder Amino bedeutet; R³ Wasserstoff oder C₁₋₄-Alkyl darstellt; R⁴ Wasserstoff ist;

35 L für einen Rest der Formel (b-1) steht, worin R⁵ Wasserstoff, C₃₋₆-Cycloalkyl, C₅₋₆-Cycloalkano- nyl, Aryl oder Het bedeutet; oder

L für einen Rest der Formel (b-2) steht, worin X die Bedeutung O, S oder NH hat und R⁶ für Wasserstoff, C₁₋₄-Alkyl, Aryl oder Het steht; oder


L für einen Rest der Formel (b-3) steht, worin Y* die Bedeutung NH oder einer direkten Bindung hat und R⁸ Wasserstoff, C₁₋₄-Alkyl, Aryl oder C₁₋₄-Alkyloxy darstellt; oder

40 L für einen Rest der Formel (b-4) steht, worin Y die Bedeutung NH oder einer direkten Bindung hat und R¹⁰ und R¹¹ jeweils unabhängig Wasserstoff, C₁₋₆-Alkyl oder Aryl bedeuten, oder R¹⁰ und R¹¹, zusammen mit dem diese Reste R¹⁰ und R¹¹ tragenden Stickstoffatom, einen Pyrrolidiny- oder Piperidinyrest ausbilden können.

- 45 3. Chemische Verbindung nach Anspruch 2, worin die Substituenten in der 3- und 4-Stellung des Piperidinrings die cis-Konfiguration aufweisen.

4. Chemische Verbindung nach Anspruch 1, worin R¹ Halogen bedeutet, R² Amino darstellt, R³ für C₁₋₄- Alkyl steht, R⁴ Wasserstoff bedeutet und A für einen Rest der Formel (a-1) oder (a-2) steht, worin das
50 dem Sauerstoffatom benachbarte Kohlenstoffatom gegebenenfalls durch einen oder zwei C₁₋₄-Alkyl- substituenten substituiert ist, oder worin A einen Rest der Formel (a-5) bedeutet.


5. Chemische Verbindung nach Anspruch 1, worin Het ein aus der aus



bestehenden Gruppe ausgewähltes cyclisches Ether- oder Thioetherringsystem bedeutet, worin jeder Rest X^1 und X^2 jeweils unabhängig für O oder S steht; m den Wert 1 oder 2 aufweist; jeder Rest R^{12} Wasserstoff, C_1-4 -Alkyl, C_1-4 -Alkyloxy- C_1-4 -alkyl oder Hydroxy- C_1-4 -alkyl darstellt und R^{13} für Wasserstoff, Halogen oder C_1-4 -Alkyl steht; oder

worin Het ein heterocyclisches Ringsystem ist, ausgewählt aus der Gruppe, bestehend aus Pyridinyl, das gegebenenfalls durch einen oder zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, Trifluormethyl, C_1-6 -Alkyloxy, Aminocarbonyl, Mono- und Di(C_1-6 -alkyl)aminocarbonyl, Amino, Mono- und Di(C_1-6 -alkyl)amino und C_1-6 -Alkyloxycarbonyl ausgewählt sind; Pyrimidinyl, das gegebenenfalls durch einen oder zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, C_1-6 -Alkyloxy, Amino und Mono- und Di(C_1-6 -alkyl)amino ausgewählt sind; Pyridazinyl, das gegebenenfalls durch C_1-6 -Alkyl oder Halogen substituiert ist; Pyrazinyl, das gegebenenfalls durch einen oder zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, C_1-6 -Alkyloxy, Amino, Mono- und Di(C_1-6 -alkyl)amino und C_1-6 -Alkyloxycarbonyl ausgewählt sind; Pyrrolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Pyrazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Imidazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Triazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Chinolinyl, das gegebenenfalls durch bis zu zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, C_1-6 -Alkyloxy, Amino, Mono- und Di(C_1-6 -alkyl)amino und Trifluormethyl ausgewählt sind; Isochinolinyl, das gegebenenfalls durch bis zu zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, C_1-6 -Alkyloxy, Amino, Mono- und Di(C_1-6 -alkyl)amino und Trifluormethyl ausgewählt sind; Chinoxalinyll, das gegebenenfalls durch bis zu zwei Substituenten substituiert ist, die jeweils unabhängig unter C_1-6 -Alkyl, Hydroxy, Halogen, Cyano und C_1-6 -Alkyloxy ausgewählt sind; Chinazolinyll, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Benzimidazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Indolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; 5,6,7,8-Tetrahydrochinolinyl, das gegebenenfalls durch bis zu zwei Substituenten substituiert ist, die jeweils unabhängig unter Halogen, Hydroxy, Cyano, C_1-6 -Alkyl, C_1-6 -Alkyloxy, Amino, Mono- und Di(C_1-6 -alkyl)amino und Trifluormethyl ausgewählt sind; 5,6,7,8-Tetrahydrochinoxalinyll, das gegebenenfalls durch bis zu zwei Substituenten substituiert ist, die jeweils unabhängig unter C_1-6 -Alkyl, Hydroxy, Halogen, Cyano und C_1-6 -Alkyloxy ausgewählt sind; Thiazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Oxazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Benzoxazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; Benzothiazolyl, das gegebenenfalls durch C_1-6 -Alkyl substituiert ist; oder

worin Het ein monocyclisches Amidringsystem darstellt, ausgewählt unter



10 worin X^3 für O oder S steht;




R^{14} Wasserstoff, C_{1-6} -Alkyl oder Aryl- C_{1-6} -alkyl darstellt;

R^{15} Wasserstoff, Halogen, C_{1-6} -Alkyl oder Aryl bedeutet;

G^1 für $-CH_2-CH_2-$, $-CH=CH-$, $-N=N-$, $-C(=O)-CH_2$ oder $-CH_2-CH_2-CH_2-$ steht, worin ein oder zwei Wasserstoffatome jeweils unabhängig durch C_{1-6} -Alkyl ersetzt sein können; und

G^2 für $-CH_2-CH_2-$, $-CH_2-N(R^{14})-$ oder $-CH_2-CH_2-CH_2-$ steht, worin ein oder zwei Wasserstoffatome jeweils unabhängig durch C_{1-6} -Alkyl ersetzt sein können; oder

worin Het ein bicyclisches Amidringsystem bedeutet, ausgewählt unter



45 worin X^4 und X^5 jeweils unabhängig für O oder S stehen;

jeder Rest R^{16} unabhängig Wasserstoff, C_{1-6} -Alkyl, oder Aryl- C_{1-6} -alkyl bedeutet;

jeder Rest R^{17} unabhängig für Wasserstoff, Halogen, C_{1-6} -Alkyl oder C_{1-6} -Alkyloxy steht; und


R^{18} Wasserstoff, Halogen, C_{1-6} -Alkyl oder Aryl darstellt;

worin die Reste (d-5), (d-6), (d-7) und (d-8) an Alk bzw. X gebunden sein können, indem entweder ein Wasserstoff oder ein Rest R^{16} und R^{17} durch eine freie Bindung ersetzt sind;

G^3 für $-CH=CH-CH=CH-$, $-(CH_2)_4-$, $-S-(CH_2)_2-$, $-S-(CH_2)_3-$, $-S-CH=CH-$, $-CH=CH-O-$, $-NH-(CH_2)_2-$, $-NH-(CH_2)_3-$, $-NH-CH=CH-$, $-NH-N=CH-CH_2-$, $-NH-CH=N-$ oder $-NH-N=CH-$ steht;


G^4 für $-CH=CH-CH=CH-$, $-CH=CCl-CH=CH-$, $-CCl=CH-CH=CH-$, $-N=CH-CH=CH-$, $-CH=N-CH=CH-$, $-CH=CH-N=CH-$, $-CH=CH-CH=N-$, $-N=CH-N=CH-$ oder $-CH=N-CH=N-$ steht.

6. Verbindung mit der Formel



eine N-Oxidform, ein therapeutisch wirksames nicht-toxisches Additionssalz oder eine stereochemisch isomere Form hiervon, worin A, R¹, R², R³ und R⁴ wie in Anspruch 1 definiert sind.

15 7. Verbindung mit der Formel



ein Salz oder eine stereochemisch isomere Form hiervon, worin A, R¹ und R² wie in Anspruch 1 definiert sind; mit der Maßgabe, daß die Verbindung von 4-Amino-5-chlor-2-methyl-2,3-dihydro-7-benzofurancarbonsäure und 4-Amino-2,3-dihydro-2,2-dimethyl-7-benzofurancarbonsäure verschieden ist.


30 8. Verbindung nach Anspruch 7, worin R¹ Chlor darstellt und R² Amino bedeutet.

35 9. Pharmazeutische Zusammensetzung, umfassend einen pharmazeutischen Träger und als wirksamen Bestandteil eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6.

40 10. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung nach Anspruch 9, dadurch gekennzeichnet, daß eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 6 innig mit einem pharmazeutischen Träger vermischt wird.


45 11. Verbindung nach einem der Ansprüche 1 bis 6 zur Verwendung als ein Medikament.

50 12. Verfahren zur Herstellung einer Verbindung nach einem der Ansprüche 1 bis 5, gekennzeichnet durch a) N-Alkylieren eines Piperidins der Formel




worin A, R¹, R², R³ und R⁴ wie in Anspruch 1 definiert sind, mit einem Zwischenprodukt der Formel L-W (III), worin W eine reaktionsfähige Leaving-Gruppe bezeichnet, in einem reaktionsinerten Lösungsmittel, gegebenenfalls in Anwesenheit einer Base und/oder eines Iodidsalzes;

b) Umsetzen eines Piperidinamins der Formel



worin R³ und R⁴ wie in Anspruch 1 definiert sind, mit einer Carbonsäure der Formel




20 oder einem funktionellen Derivat hiervon, worin, A, R¹ und R² wie in Anspruch 1 definiert sind, in einem reaktionsinerten Lösungsmittel, gegebenenfalls in Anwesenheit eines zur Bildung von Amidien befähigten Reagens; oder

25 c) reduktives N-Alkylieren einer Verbindung der Formel HD (II) mit einem Keton oder Aldehyd der Formel L' = O (VI), worin L' = O eine Verbindung der Formel L-H bedeutet, worin zwei geminale Wasserstoffatome in diesem C₁-₆-Alkandiyl oder C₃-₆-Cycloalkandiyl durch =O ersetzt sind, in einem reaktionsinerten Medium;


30 oder gewünschtenfalls Überführen der Verbindungen der Formel (I) ineinander nach bekannten funktionellen Gruppentransformationsreaktionen, und gewünschtenfalls Überführen einer Verbindung der Formel (I) in ein therapeutisch wirksames nichttoxisches Salz durch Behandlung mit einer entsprechenden Säure, oder umgekehrt Überführen einer Salzform in eine freie Basenform mit Alkali; und/oder Bereiten der N-Oxidformen und der stereochemisch isomeren Formen hiervon.

- 35 13. Verfahren zur Herstellung einer Verbindung der Formel Het-X-Alk-D (I-b-2) nach Anspruch 1, worin Het, X und Alk wie in Anspruch 1 definiert sind und D den Rest



50 darstellt, worin A, R¹, R², R³ und R⁴ wie in Anspruch 1 definiert sind, gekennzeichnet durch Umsetzen eines Reagens der Formel Het-W¹ (VII) oder Het-X-H (VIII) mit einem Piperidin der Formel, HX-Alk-D (I-b-2-a) bzw. W²-Alk-D (IX), worin W¹ und W² beide reaktionfähige Leaving-Gruppen bezeichnen, in einem reaktionsinerten Lösungsmittel unter Ausbildung einer Verbindung der Formel Het-X-Alk-D (I-b-2-b).

- 55 14. Verfahren zur Herstellung einer Verbindung der Formel NC-CH₂-CH₂-D (I-c) nach Anspruch 1, worin D den Rest



5


10

darstellt, worin A, R¹, R², R³ und R⁴ die gleiche Bedeutung wie in Anspruch 1 aufweisen, gekennzeichnet durch Alkylieren eines Piperidins der Formel H-D (II) mit CH₂=CH-CN (XV) in einem reaktionsinerten Lösungsmittel unter Ausbildung einer Verbindung der Formel NC-CH₂-CH₂-D (I-c); und gewünschtenfalls Reduzieren dieser Verbindung zum entsprechenden Amin in einem wasserstoffhaltigen Medium in Anwesenheit eines Katalysators.

15

15. Verfahren zur Herstellung einer Verbindung nach Anspruch 6, gekennzeichnet durch Umsetzen eines Piperidinamins der Formel


20



25

worin P¹ eine Schutzgruppe darstellt und R³ und R⁴ wie in Anspruch 1 definiert sind, mit einer Carbonsäure der Formel

30




35

40

oder einem funktionellen Derivat hiervon, worin A, R¹ und R² wie in Anspruch 1 definiert sind, und anschließendes Abtrennen der Schutzgruppe P¹ aus dem solcherart erhaltenen Zwischenprodukt

45




50

55

nach bekannten Methoden in einem reaktionsinerten Lösungsmittel, und gewünschtenfalls Überführen einer Verbindung der Formel (I) in ein therapeutisch wirksames nicht-toxisches Salz durch Behandlung mit einer entsprechenden Säure, oder umgekehrt Überführen einer Salzform in eine freie Basenform mit Alkali; und/oder Bereiten der N-Oxidformen und der stereochemisch isomeren Formen hiervon.

Patentansprüche für folgende Vertragsstaaten : ES, GR

1. Verfahren zur Herstellung einer Verbindung der Formel



15 einer N-Oxidform, eines therapeutisch wirksamen nichttoxischen Additionssalzes oder einer stereochemisch isomeren Form hiervon, worin:

A für einen Rest der Formel

20 -CH₂-CH₂- (a-1),

-CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

25 -CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5)

oder

30 -CH₂-CH₂-CH₂-O- (a-6)

steht, worin ein oder zwei Wasserstoffatome in diesen Resten (a-1) bis (a-6) durch einen C₁₋₆-Alkylrest ersetzt sein können;

R¹ Wasserstoff oder Halogen bedeutet;

R² für Amino, Mono- oder Di(C₁₋₆-alkyl)amino, Aryl-C₁₋₆-alkylamino oder C₁₋₆-Alkylcarbonylamino steht;

R³ und R⁴ jeweils unabhängig Wasserstoff oder C₁₋₆-Alkyl bedeuten;

40 L für C₃₋₆-Cycloalkyl, C₅₋₆-Cycloalkanonyl, gegebenenfalls durch Aryl substituiertes C₃₋₆-Alkenyl steht oder L einen Rest der Formel

-Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

45 -Alk-Y-C(=O)-R⁸ (b-3)

oder

50 -Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4)

bedeutet, worin Alk jeweils C₁₋₆-Alkandiy l darstellt; und

R⁵ für Wasserstoff, Cyano, C₁₋₆-Alkylsulfonylamino, C₃₋₆-Cycloalkyl, C₅₋₆-Cycloalkanonyl, Aryl, Di(aryl)methyl oder Het steht;

55 R⁶ Wasserstoff, C₁₋₆-Alkyl, C₃₋₆-Cycloalkyl, Aryl oder Het bedeutet;

X für O, S, SO₂ oder NR⁷ steht; worin der genannte Rest R⁷ Wasserstoff, C₁₋₆-Alkyl oder Aryl darstellt;

R⁸ für Wasserstoff, C₁₋₆-Alkyl, C₃₋₆-Cycloalkyl, Aryl, Aryl-C₁₋₆-alkyl, Di(aryl)methyl oder C₁₋₆-

Alkyloxy steht;

Y für NR^9 oder eine direkte Bindung steht; welcher Rest R^9 Wasserstoff, C_1 - C_6 -Alkyl oder Aryl darstellt;


R^{10} und R^{11} jeweils unabhängig Wasserstoff, C_1 - C_6 -Alkyl, C_3 - C_6 -Cycloalkyl, Aryl oder Aryl- C_1 - C_6 -alkyl bedeuten, oder R^{10} und R^{11} zusammen mit dem die Reste R^{10} und R^{11} tragenden Stickstoffatom einen Pyrrolidiny- oder Piperidiny- oder Piperaziny- oder 4-Morpholiny- oder 4-Morpholinylrest bilden können, die beide gegebenenfalls durch C_1 - C_6 -Alkyl substituiert sind;

jedes Aryl unsubstituiertes Phenyl oder durch 1, 2 oder 3 Substituenten substituiertes Phenyl darstellt, welche Substituenten jeweils unabhängig unter Halogen, Hydroxy, C_1 - C_6 -Alkyl, C_1 - C_6 -Alkyloxy, Aminosulfonyl, C_1 - C_6 -Alkylcarbonyl, Nitro, Trifluormethyl, Amino oder Aminocarbonyl ausgewählt sind; und

jedes Het einen fünf- oder sechsgliedrigen heterocyclischen Ring mit einem Gehalt an 1, 2, 3 oder 4, unter Sauerstoff, Schwefel und Stickstoff ausgewählten Heteroatomen bedeutet, mit der Maßgabe, daß nicht mehr als 2 Sauerstoff- und/oder Schwefelatome vorliegen, wobei dieser fünf- oder sechsgliedrige Ring gegebenenfalls mit einem fünf- oder sechsgliedrigen carbocyclischen Ring oder heterocyclischen Ring, der ebenfalls 1, 2, 3 oder 4, unter Sauerstoff, Schwefel und Stickstoff ausgewählte Heteroatome enthält, kondensiert ist, mit der Maßgabe, daß der letztgenannte Ring nicht mehr als 2 Sauerstoff- und/oder Schwefelatome enthält und daß die Gesamtanzahl von Heteroatomen in dem bicyclischen Ringsystem kleiner als 6 ist; wobei dann, wenn Het ein monocyclisches Ringsystem bedeutet, dieses gegebenenfalls durch bis zu 4 Substituenten substituiert sein kann; und wenn Het ein bicyclisches Ringsystem darstellt, dieses gegebenenfalls durch bis zu 6 Substituenten substituiert sein kann; welche Substituenten aus der aus Halogen, Hydroxy, Cyano, Trifluormethyl, C_1 - C_6 -Alkyl, Aryl- C_1 - C_6 -alkyl, Aryl, C_1 - C_6 -Alkyloxy, C_1 - C_6 -Alkyloxy- C_1 - C_6 -alkyl, Hydroxy- C_1 - C_6 -alkyl, C_1 - C_6 -Alkylthio, Mercapto, Nitro, Amino, Mono- und Di(C_1 - C_6 -alkyl)amino, Aryl- C_1 - C_6 -alkylamino, Aminocarbonyl, Mono- und Di(C_1 - C_6 -alkyl)aminocarbonyl, C_1 - C_6 -Alkyloxycarbonyl, Aryl- C_1 - C_6 -alkyloxycarbonyl, einem zweiwertigen Rest $=\text{O}$ und $=\text{S}$ bestehenden Gruppe ausgewählt sind; mit der Maßgabe, daß dann, wenn R^6 für Het steht, Het an einem Kohlenstoffatom an X gebunden ist;


gekennzeichnet durch

a) N-Alkylieren eines Piperidins der Formel




worin A, R^1 , R^2 , R^3 und R^4 wie in Anspruch 1 definiert sind, mit einem Zwischenprodukt der Formel L-W (III), worin W eine reaktionsfähige Leaving-Gruppe bezeichnet, in einem reaktionsinerten Lösungsmittel, gegebenenfalls in Anwesenheit einer Base und/oder eines Iodidsalzes;

b) Umsetzen eines Piperidinamins der Formel



worin R^3 und R^4 wie in Anspruch 1 definiert sind, mit einer Carbonsäure der Formel




10 oder einem funktionellen Derivat hiervon, worin A, R¹ und R² wie in Anspruch 1 definiert sind, in einem reaktionsinerten Lösungsmittel, gegebenenfalls in Anwesenheit eines zur Bildung von Amidon befähigten Reagens; oder

15 c) reduktives N-Alkylieren einer Verbindung der Formel HD (II) mit einem Keton oder Aldehyd der Formel L'=O (VI), worin L'=O eine Verbindung der Formel L-H bedeutet, worin zwei geminale Wasserstoffatome in diesem C₁₋₆-Alkandiyl oder C₃₋₆-Cycloalkandiyl durch =O ersetzt sind, in einem reaktionsinerten Medium;


20 oder gewünschtenfalls Überführen der Verbindungen der Formel (I) ineinander nach bekannten funktionellen Gruppentransformationsreaktionen, und gewünschtenfalls Überführen einer Verbindung der Formel (I) in ein therapeutisch wirksames nichttoxisches Salz durch Behandlung mit einer entsprechenden Säure, oder umgekehrt Überführen einer Salzform in eine freie Basenform mit Alkali; und/oder Bereiten der N-Oxidformen und der stereochemisch isomeren Formen hiervon.

- 25 2. Verfahren zur Herstellung einer Verbindung der Formel Het-X-Alk-D (I-b-2), worin Het, X und Alk wie in Anspruch 1 definiert sind und D den Rest




40 darstellt, worin A, R¹, R², R³ und R⁴ wie in Anspruch 1 definiert sind, gekennzeichnet durch Umsetzen eines Reagens der Formel Het-W¹ (VII) oder Het-X-H (VIII) mit einem Piperidin der Formel HX-Alk-D (I-b-2-a) bzw. W²-Alk-D (IX), worin W¹ und W² beide reaktionsfähige Leaving-Gruppen bezeichnen, in einem reaktionsinerten Lösungsmittel unter Ausbildung einer Verbindung der Formel Het-X-Alk-D (I-b-2-b).

- 45 3. Verfahren zur Herstellung einer Verbindung der Formel NC-CH₂-CH₂-D (I-c), worin D den Rest




darstellt, worin A, R¹, R², R³ und R⁴ die gleiche Bedeutung wie in Anspruch 1 aufweisen, gekennzeichnet durch Alkylieren eines Piperidins der Formel H-D (II) mit CH₂=CH-CN (XV) in einem reaktionsinerten Lösungsmittel unter Ausbildung einer Verbindung der Formel NC-CH₂-CH₂-D (I-c); und gewünschtenfalls Reduzieren dieser Verbindung zum entsprechenden Amin in einem wasserstoffhaltigen Medium in Anwesenheit eines Katalysators.

4. Verfahren zur Herstellung einer Verbindung




einer N-Oxidform, eines therapeutisch wirksamen nicht-toxischen Additionssalzes oder einer stereochemisch isomeren Form hiervon, worin A, R¹, R², R³ und R⁴ wie in Anspruch 1 definiert sind, gekennzeichnet durch Umsetzen eines Piperidinamins der Formel

15




worin P¹ eine Schutzgruppe darstellt und R³ und R⁴ wie in Anspruch 1 definiert sind, mit einer Carbonsäure der Formel

25



oder einem funktionellen Derivat hiervon, worin A, R¹ und R² wie in Anspruch 1 definiert sind, und anschließendes Abtrennen der Schutzgruppe P¹ aus dem solcherart erhaltenen Zwischenprodukt

35



nach bekannten Methoden in einem reaktionsinerten Lösungsmittel, und gewünschtenfalls Überführen einer Verbindung der Formel (I) in ein therapeutisch wirksames nicht-toxisches Salz durch Behandlung mit einer entsprechenden Säure, oder umgekehrt Überführen einer Salzform in eine freie Basenform mit Alkali; und/oder Bereiten der N-Oxidformen und der stereochemisch isomeren Formen hiervon.


50

55

Revendications

Revendications pour les Etats contractants suivants : AT, BE, CH, DE, DK, FR, GB, IT, LI, LU, NL, SE

1. Composé chimique de formule



15

forme N-oxyde, sel d'addition thérapeutiquement actif et non toxique, ou forme stéréochimiquement isomère de celui-ci, formule dans laquelle

A est un radical de formule

20 -CH₂-CH₂- (a-1),

-CH₂-CH₂-CH₂- (a-2),

-CH₂-CH₂-CH₂-CH₂- (a-3),

25 -CH₂-O- (a-4),

-CH₂-CH₂-O- (a-5)

30 ou

-CH₂-CH₂-CH₂-O- (a-6),

35 un ou deux atomes d'hydrogène dans lesdits radicaux (a-1) à (a-6) pouvant être remplacés par un radical alkyle en C₁-C₆;

R¹ est un atome d'hydrogène ou d'halogène;

R² est un groupe amino, mono- ou dialkyl(C₁-C₆)amino, aryl-alkyl(C₁-C₆)amino ou alkyl-(C₁-C₆)-carbonylamino;

R³ et R⁴ sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C₁-C₆;

40 L est un radical cycloalkyle en C₃-C₆, cycloalcanonyle en C₅-C₆, alcényle en C₃-C₆ éventuellement substitué par un groupe aryle, ou

L est un radical de formule

-Alk-R⁵ (b-1),

45 -Alk-X-R⁶ (b-2),

-Alk-Y-C(=O)-R⁸ (b-3)

50 ou

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4),

55 formules dans lesquelles

chaque reste Alk est un groupe alcanediyle en C₁-C₆; et

R⁵ est un atome d'hydrogène ou un groupe cyano, alkyl(C₁-C₆)sulfonylamino, cycloalkyle en C₃-C₆, cycloalcanonyle en C₅-C₆, aryle, di(aryl)méthyle ou Het;

R⁶ est un atome d'hydrogène ou un groupe alkyle en C₁-C₆, cycloalkyle en C₃-C₆, aryle ou

- Het;
- X est O, S, SO₂ ou NR⁷; ledit radical R⁷ étant un atome d'hydrogène ou un groupe alkyle en C₁₋₆ ou aryle;
- R⁸ est un atome d'hydrogène ou un groupe alkyle en C₁₋₆, cycloalkyle en C₃₋₆, aryle, aryl-alkyle(C₁₋₆), di(aryl)méthyle ou alkyloxy en C₁₋₆;
- Y est NR⁹ ou une liaison directe; ledit reste R⁹ étant un atome d'hydrogène ou un groupe alkyle en C₁₋₆ ou aryle;
- R¹⁰ et R¹¹ sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C₁₋₆; cycloalkyle en C₃₋₆, aryle ou aryl-alkyle(C₁₋₆), ou R¹⁰ et R¹¹, conjointement avec l'atome d'azote portant R¹⁰ et R¹¹, peuvent former un cycle pyrrolidinyle ou pipéridinyle, l'un et l'autre étant éventuellement substitués par des groupes alkyle en C₁₋₆, amino ou mono- ou dialkyl(C₁₋₆)amino, ou lesdits radicaux R¹⁰ et R¹¹ réunis avec l'atome d'azote portant R¹⁰ et R¹¹ peuvent former un radical pipérazinyle ou 4-morpholinyle, l'un et l'autre étant éventuellement substitués par des groupes alkyle en C₁₋₆;

chaque fragment aryle étant le groupe phényle non substitué ou un groupe phényle substitué par 1, 2 ou 3 substituants indépendamment choisis chacun parmi des atomes d'halogène et des groupes hydroxy, alkyle en C₁₋₆, alkyloxy en C₁₋₆, aminosulfonyl, alkyl(C₁₋₆)carbonyl, nitro, trifluorométhyle, amino ou aminocarbonyl; et

chaque radical Het étant un cycle hétérocyclique à 5 ou 6 chaînons contenant 1, 2, 3 ou 4 hétéroatomes choisis parmi les atomes d'oxygène, de soufre et d'azote, étant entendu que 2 atomes d'oxygène et/ou de soufre au maximum sont présents, ledit cycle à 5 ou 6 chaînons étant éventuellement soudé à un cycle carbocyclique ou hétérocyclique à 5 ou 6 chaînons, contenant également 1, 2, 3 ou 4 hétéroatomes choisis parmi les atomes d'oxygène, de soufre et d'azote, étant entendu que ce dernier cycle ne contient pas plus de 2 atomes d'oxygène et/ou de soufre, et que le nombre total des hétéroatomes dans le système cyclique bicyclique est inférieur à 6; lorsque Het est un système cyclique monocyclique, il peut éventuellement être substitué par jusqu'à 4 substituants; lorsque Het est un système cyclique bicyclique, il peut éventuellement être substitué par jusqu'à 6 substituants; lesdits substituants étant choisis parmi des atomes d'halogène et des groupes hydroxy, cyano, trifluorométhyle, alkyle en C₁₋₆, aryl-alkyle(C₁₋₆), aryle, alkyloxy en C₁₋₆, alkyloxy(C₁₋₆)-alkyle(C₁₋₆), hydroxyalkyle en C₁₋₆, alkyl(C₁₋₆)thio, mercapto, nitro, amino, mono- et dialkyl(C₁₋₆)amino, aryl-alkyl(C₁₋₆)amino, aminocarbonyl, mono- et dialkyl(C₁₋₆)aminocarbonyl, alkyloxy(C₁₋₆)carbonyl, arylalkyloxy(C₁₋₆)carbonyl, un radical bivalent =O ou =S; étant entendu que lorsque R⁶ est Het, Het est lié à X sur un atome de carbone.


2. Composé chimique selon la revendication 1, dans lequel

- R¹ est un atome d'hydrogène ou d'halogène; R² est un atome d'hydrogène ou le groupe amino; R³ est un atome d'hydrogène ou un groupe alkyle en C₁₋₄; R⁴ est un atome d'hydrogène;
- L est un radical de formule (b-1) dans lequel R⁵ est un atome d'hydrogène ou un groupe cycloalkyle en C₃₋₆, cycloalcanonyl en C₅₋₆, aryle ou Het; ou
- L est un radical de formule (b-2) dans lequel X est O, S ou NH, et R⁶ est un atome d'hydrogène ou un groupe alkyle en C₁₋₄, aryle ou Het; ou
- L est un radical de formule (b-3) dans lequel Y est NH ou une liaison directe, et R⁸ est un atome d'hydrogène ou un groupe alkyle en C₁₋₄, aryle ou alkyloxy en C₁₋₄; ou
- L est un radical de formule (b-4) dans lequel Y est NH ou une liaison directe, et R¹⁰ et R¹¹ sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C₁₋₄ ou aryle, ou R¹⁰ et R¹¹, réunis avec l'atome d'azote portant lesdits radicaux R¹⁰ et R¹¹, peuvent former un radical pyrrolidinyle ou pipéridinyle.

3. Composé chimique selon la revendication 2, dans lequel les substituants en positions 3 et 4 du cycle pipéridine sont en configuration *cis*.

4. Composé chimique selon la revendication 1, dans lequel R¹ est un atome d'halogène, R² est le groupe amino, R³ est un groupe alkyle en C₁₋₄, R⁴ est un atome d'hydrogène et A est un radical de formule (a-1) ou (a-2) dans lequel l'atome de carbone adjacent à l'atome d'oxygène est éventuellement substitué par un ou deux substituants alkyle en C₁₋₄, ou A est un radical de formule (a-5).


5. Composé chimique selon la revendication 1, dans lequel Het est un système cyclique de type éther ou thioéther cyclique choisi parmi ceux de formules



dans lesquelles les radicaux X^1 et X^2 sont chacun indépendamment O ou S; m est 1 ou 2; chaque radical R^{12} est un atome d'hydrogène ou un groupe alkyle en C_{1-4} , alkyloxy(C_{1-4})-alkyle(C_{1-4}) ou hydroxyalkyle en C_{1-4} ; et R^{13} est un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_{1-4} ; ou

dans lequel Het est un système cyclique hétérocyclique choisi parmi un radical pyridinyle qui est éventuellement substitué par un ou deux substituants, choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , trifluorométhyle, alkyloxy en C_{1-6} , aminocarbonyle, mono- et dialkyl(C_{1-6})aminocarbonyle, amino, mono- et dialkyl(C_{1-6})amino, et alkyloxy(C_{1-6})carbonyle; un radical pyrimidinyle qui est éventuellement substitué par un ou deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , alkyloxy en C_{1-6} , amino et mono- et dialkyl(C_{1-6})amino; un radical pyridazinyle qui est éventuellement substitué par un atome d'halogène ou par un groupe alkyle en C_{1-6} ; un radical pyrazinyle qui est éventuellement substitué par un ou deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , alkyloxy en C_{1-6} , amino, mono- et dialkyl(C_{1-6})amino et alkyloxy(C_{1-6})carbonyle; un radical pyrrolyle qui est éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical pyrazolyle qui est éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical imidazolyle qui est éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical triazolyle qui est éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical quinolinyle éventuellement substitué par jusqu'à deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , alkyloxy en C_{1-6} , amino, mono- et dialkyl(C_{1-6})amino et trifluorométhyle; un radical isoquinolinyle éventuellement substitué par jusqu'à deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , alkyloxy en C_{1-6} , amino, mono- et dialkyl(C_{1-6})amino et trifluorométhyle; un radical quinoxalinyle éventuellement substitué par jusqu'à deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano et alkyloxy en C_{1-6} ; un radical quinazolinyle éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical benzimidazolyle éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical indolyle éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical 5,6,7,8-tétrahydroquinolinyle éventuellement substitué par jusqu'à deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes hydroxy, cyano, alkyle en C_{1-6} , alkyloxy en C_{1-6} , amino, mono- et dialkyl(C_{1-6})amino et trifluorométhyle; un radical 5,6,7,8-tétrahydroquinoxalinyle éventuellement substitué par jusqu'à deux substituants choisis chacun indépendamment parmi des atomes d'halogène et des groupes alkyle en C_{1-6} , hydroxy, cyano et alkyloxy en C_{1-6} ; un radical thiazolyle éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical oxazolyle éventuellement substitué par un groupe alkyle en C_{1-6} ; un radical benzoxazolyle éventuellement substitué par un radical alkyle en C_{1-6} ; un radical benzothiazolyle éventuellement substitué par un groupe alkyle en C_{1-6} ; ou

dans lequel Het est un système cyclique de type amide monocyclique choisi parmi ceux de formules



10 dans lesquelles

X^3 est O ou S;


R^{14} est un atome d'hydrogène ou un groupe alkyle en C_{1-6} ou aryl-alkyle(C_{1-6});

R^{15} est un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_{1-6} ou aryle;

15 G^1 est $-CH_2-CH_2-$, $-CH=CH-$, $-N=N-$, $-C(=O)-CH_2-$ ou $-CH_2-CH_2-CH_2-$, un ou deux atomes d'hydrogène pouvant être remplacés chacun indépendamment par un groupe alkyle en C_{1-6} ; et

G^2 est $-CH_2-CH_2-$, $-CH_2-N(R^{14})-$ ou $-CH_2-CH_2-CH_2-$, un ou deux atomes d'hydrogène pouvant être remplacés chacun indépendamment par un groupe alkyle en C_{1-6} ; ou

20 dans lequel Het est un système cyclique de type amide bicyclique choisi parmi ceux de formules



50 dans lesquelles

X^4 et X^5 sont chacun indépendamment O ou S;

chaque radical R^{16} est indépendamment un atome d'hydrogène ou un groupe alkyle en C_{1-6} ou aryl-alkyle(C_{1-6});


chaque radical R^{17} est indépendamment un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_{1-6} ou alkyloxy en

55 R^{18} est un atome d'hydrogène ou d'halogène ou un groupe alkyle en C_{1-6} ou aryle;

les radicaux (d-5), (d-6), (d-7) et (d-8) pouvant être reliés à respectivement Alk ou X, par remplacement d'un atome d'hydrogène ou des radicaux R^{16} et R^{17} par une liaison libre;


- G³ est -CH=CH-CH=CH-, -(CH₂)₄-, -S-(CH₂)₂-, -S-(CH₂)₃-, -S-CH=CH-, -CH=CH-O-, -NH-(CH₂)₂-, -NH-(CH₂)₃-, -NH-CH=CH-, -NH-N=CH-CH₂-, -NH-CH=N- ou -NH-N=CH-;
- G⁴ est -CH=CH-CH=CH-, -CH=CCl-CH=CH-, -CCl=CH-CH=CH-, -N=CH-CH=CH-, =CH=N-CH=CH-, -CH=CH-N=CH-, -CH=CH-CH=N-, -N=CH-N=CH- ou -CH=N-CH=N-.

6. Composé de formule



forme N-oxyde, sel d'addition thérapeusement actif et non toxique ou forme stéréochimiquement isomère de celui-ci, dans lequel A, R¹, R², R³ et R⁴ sont tels que définis dans la revendication 1.

7. Composé de formule



sel ou forme stéréochimiquement isomère de celui-ci, dans lequel A, R¹ et R² sont tels que définis dans la revendication 1; étant entendu que le composé est différent de l'acide 4-amino-5-chloro-2-méthyl-2,3-dihydro-7-benzofuranecarboxylique et de l'acide 4-amino-2,3-dihydro-2,2-diméthyl-7-benzofuranecarboxylique.

8. Composé selon la revendication 7, dans lequel R¹ est un atome de chlore et R² est le groupe amino.


9. Composition pharmaceutique comprenant un véhicule pharmaceutique et, en tant que composant actif, une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 6.

10. Procédé de préparation d'une composition pharmaceutique selon la revendication 9, caractérisé en ce que l'on mélange intimement une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 6 avec un véhicule pharmaceutique.

11. Composé selon l'une quelconque des revendications 1 à 6, pour utilisation en tant que médicament.


12. Procédé pour la préparation d'un composé selon l'une quelconque des revendications 1 à 5, caractérisé par

a) la N-alkylation d'une pipéridine de formule




dans laquelle A, R¹, R², R³ et R⁴ sont tels que définis dans la revendication 1, avec un produit intermédiaire de formule L-W (III) dans laquelle W est un groupe partant réactif, dans un solvant inerte à l'égard de la réaction, éventuellement en présence d'une base et/ou d'un iodure;

b) la mise en réaction d'une pipéridinamine de formule



dans laquelle R³ et R⁴ sont tels que définis dans la revendication 1, avec un acide carboxylique de formule




ou un dérive fonctionnel de celui-ci, dans lequel A, R¹ et R² sont tels que définis dans la revendication 1, dans un solvant inerte à l'égard de la réaction, éventuellement en présence d'un réactif capable de former des amides; ou

c) la N-alkylation réductrice d'un composé de formule HD (II) avec une cétone ou un aldéhyde de formule L'=O (VI) dans laquelle L'=O est un composé de formule L-H dans lequel deux atomes d'hydrogène géminés dans ledit radical alcane(C₁-ε)diyle ou cycloalcane(C₃-ε)diyle sont remplacés par =O, dans un milieu inerte à l'égard de la réaction;

ou éventuellement la conversion des composés de formule (I) entre eux, selon des réactions de transformation de groupes fonctionnels connues dans la technique, et, si on le désire la conversion d'un composé de formule (I) en un sel thérapeutiquement actif et non toxique, par traitement par un acide approprié, ou, inversement, la conversion d'une forme sel en une forme base libre à l'aide d'une solution alcaline; et/ou la préparation des formes N-oxyde et des formes stéréochimiquement isomères de ces composés.


13. Procédé pour la préparation d'un composé de formule Het-X-Alk-D (I-b-2-b) selon la revendication 1, dans lequel Het, X et Alk sont tels que définis dans la revendication 1 et D représente le radical



dans lequel A, R^1 , R^2 , R^3 et R^4 sont tels que définis dans la revendication 1, caractérisé par la mise en réaction d'un réactif de formule Het- W^1 (VII) ou Het-X-H (VIII) avec une pipéridine de formule


HX-Alk-D (I-b-2-a) ou W^2 -Alk-D (IX), respectivement, W^1 et W^2 étant l'un et l'autre des groupes partants réactifs, dans un solvant inerte à l'égard de la réaction, pour l'obtention d'un composé de formule Het-X-Alk-D (I-b-2-b).

14. Procédé pour la préparation d'un composé de formule NC-CH₂-CH₂-D (I-c); selon la revendication 1, dans laquelle D représente le radical




dans lequel A, R^1 , R^2 , R^3 et R^4 ont les mêmes significations que dans la revendication 1, caractérisé par l'alkylation d'une pipéridine de formule H-D (II) avec CH₂=CH-CN (XV) dans un solvant inerte à l'égard de la réaction, pour l'obtention d'un composé de formule NC-CH₂-CH₂-D (I-c); et éventuellement la réduction dudit composé en l'amine correspondante, dans un milieu contenant de l'hydrogène, en présence d'un catalyseur.


15. Procédé pour la préparation d'un composé selon la revendication 6, caractérisé par la mise en réaction d'une pipéridinamine de formule



dans laquelle P^1 représente un groupe protecteur et R^3 et R^4 sont tels que définis dans la revendication 1, avec un acide carboxylique de formule



ou un dérivé fonctionnel de celui-ci, dans lequel A, R¹ et R² sont tels que définis dans la revendication 1, et ensuite l'élimination du groupe protecteur P¹ dans le produit intermédiaire




15

ainsi obtenu, selon des modes opératoires connus dans la technique, dans un solvant inerte à l'égard de la réaction et, si, on le désire, la conversion d'un composé de formule (I) en un sel thérapeutiquement actif et non toxique, par traitement par un acide approprié, ou, inversement, la conversion d'une forme sel en une forme base libre à l'aide d'une solution alcaline; et/ou la préparation des formes N-oxyde et des formes stéréochimiquement isomères de ce composé.

20 **Revendications pour les Etats contractants suivants : ES, GR**





1. Procédé pour la préparation d'un composé chimique de formule




35

d'une forme N-oxyde, d'un sel d'addition thérapeutiquement actif et non toxique, ou d'une forme stéréochimiquement isomère de celui-ci, formule dans laquelle

A est un radical de formule



ou



un ou deux atomes d'hydrogène dans lesdits radicaux (a-1) à (a-6) pouvant être remplacés par un radical alkyle en C₁-C₆;

55 R¹ est un atome d'hydrogène ou d'halogène;

R² est un groupe amino, mono- ou dialkyl(C₁-C₆)amino, aryl-alkyl(C₁-C₆)amino ou alkyl-(C₁-C₆)-carbonylamino;

R³ et R⁴ sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C₁-C₆;

L est un radical cycloalkyle en C₃₋₆, cycloalcanonyl en C₅₋₆, alcényle en C₃₋₆ éventuellement substitué par un groupe aryle, ou
 L est un radical de formule

5 -Alk-R⁵ (b-1),

-Alk-X-R⁶ (b-2),

10 -Alk-Y-C(=O)-R⁸ (b-3)

ou

-Alk-Y-C(=O)-NR¹⁰R¹¹ (b-4),

15 formules dans lesquelles

chaque reste Alk est un groupe alcanediyle en C₁₋₆; et

R⁵ est un atome d'hydrogène ou un groupe cyano, alkyl(C₁₋₆)sulfonylamino, cycloalkyle en C₃₋₆, cycloalcanonyl en C₅₋₆, aryle, di(aryl)méthyle ou Het;

20 R⁶ est un atome d'hydrogène ou un groupe alkyle en C₁₋₆, cycloalkyle en C₃₋₆, aryle ou Het;

X est O, S, SO₂ ou NR⁷; ledit radical R⁷ étant un atome d'hydrogène ou un groupe alkyle en C₁₋₆ ou aryle;

R⁸ est un atome d'hydrogène ou un groupe alkyle en C₁₋₆, cycloalkyle en C₃₋₆, aryle, aryl-alkyle(C₁₋₆), di(aryl)méthyle ou alkyloxy en C₁₋₆;

25 Y est NR⁹ ou une liaison directe; ledit reste R⁹ étant un atome d'hydrogène ou un groupe alkyle en C₁₋₆ ou aryle;


R¹⁰ et R¹¹ sont chacun indépendamment un atome d'hydrogène ou un groupe alkyle en C₁₋₆, cycloalkyle en C₃₋₆, aryle ou aryl-alkyle(C₁₋₆), ou R¹⁰ et R¹¹ conjointement avec l'atome d'azote portant R¹⁰ et R¹¹, peuvent former un cycle pyrrolidinyle ou pipéridinyle, l'un et l'autre étant éventuellement substitués par des groupes alkyle en C₁₋₆, amino ou mono- ou dialkyl(C₁₋₆)amino, ou lesdits radicaux R¹⁰ et R¹¹ réunis avec l'atome d'azote portant R¹⁰ et R¹¹ peuvent former un radical pipérazinyle ou 4-morpholinyle, l'un et l'autre étant éventuellement substitués par des groupes alkyle en C₁₋₆;

35 chaque fragment aryle étant le groupe phényle non substitué ou un groupe phényle substitué par 1, 2 ou 3 substituants indépendamment choisis chacun parmi des atomes d'halogène et des groupes hydroxy, alkyle en C₁₋₆, alkyloxy en C₁₋₆, aminosulfonyl, alkyl(C₁₋₆)carbonyl, nitro, trifluorométhyle, amino ou aminocarbonyl; et

40 chaque radical Het étant un cycle hétérocyclique à 5 ou 6 chaînons contenant 1, 2, 3 ou 4 hétéroatomes choisis parmi les atomes d'oxygène, de soufre et d'azote, étant entendu que 2 atomes d'oxygène et/ou de soufre au maximum sont présents, ledit cycle à 5 ou 6 chaînons étant éventuellement soudé à un cycle carbocyclique ou hétérocyclique à 5 ou 6 chaînons, contenant également 1, 2, 3 ou 4 hétéroatomes choisis parmi les atomes d'oxygène, de soufre et d'azote, étant entendu que ce dernier cycle ne contient pas plus de 2 atomes d'oxygène et/ou de soufre, et que le nombre total des hétéroatomes dans le système cyclique bicyclique est inférieur à 6; lorsque Het est un système cyclique mono-cyclique, il peut éventuellement être substitué par jusqu'à 4 substituants; lorsque Het est un système cyclique bicyclique, il peut éventuellement être substitué par jusqu'à 6 substituants; lesdits substituants étant choisis parmi des atomes d'halogène et des groupes hydroxy, cyano, trifluorométhyle, alkyle en C₁₋₆, aryl-alkyle(C₁₋₆), aryle, alkyloxy en C₁₋₆, alkyloxy(C₁₋₆)-alkyle(C₁₋₆), hydroxyalkyle en C₁₋₆, alkyl(C₁₋₆)thio, mercapto, nitro, amino, mono- et dialkyl(C₁₋₆)amino, aryl-alkyl(C₁₋₆)amino, aminocarbonyl, mono- et dialkyl(C₁₋₆)aminocarbonyl, alkyloxy(C₁₋₆)carbonyl, arylalkyloxy(C₁₋₆)carbonyl, un radical bivalent =O ou =S; étant entendu que lorsque R⁶ est Het, Het est lié à X sur un atome de carbone;


55 caractérisé par

a) la N-alkylation d'une pipéridine de formule




dans laquelle A, R¹, R², R³ et R⁴ sont tels que définis plus haut, avec un produit intermédiaire de formule L-W (III) dans laquelle W est un groupe partant réactif; dans un solvant inerte à l'égard de la réaction, éventuellement en présence d'une base et/ou d'un iodure;

b) la mise en réaction d'une pipéridinamine de formule



dans laquelle R³ et R⁴ sont tels que définis plus haut, avec un acide carboxylique de formule




ou un dérivé fonctionnel de celui-ci, dans lequel A, R¹ et R² sont tels que définis plus haut, dans un solvant inerte à l'égard de la réaction, éventuellement en présence d'un réactif capable de former des amides; ou

c) la N-alkylation réductrice d'un composé de formule HD (II) avec une cétone ou un aldéhyde de formule L'=O (VI) dans laquelle L'=O est un composé de formule L-H dans lequel deux atomes d'hydrogène géminés dans ledit radical alcane(C₁-₆)diyle ou cycloalcane(C₃-₆)diyle sont remplacés par =O, dans un milieu inerte à l'égard de la réaction;

ou éventuellement la conversion des composés de formule (I) entre eux, selon des réactions de transformation de groupes fonctionnels connues dans la technique, et, si on le désire la conversion d'un composé de formule (I) en un sel thérapeutiquement actif et non toxique, par traitement par un acide approprié, ou, inversement, la conversion d'une forme sel en une forme base libre à l'aide d'une solution alcaline; et/ou la préparation des formes N-oxyde et des formes stéréochimiquement isomères de ces composés.


2. Procédé pour la préparation d'un composé de formule Het-X-Alk-D (I-b-2-b), dans lequel Het, X et Alk sont tels que définis dans la revendication 1 et D représente le radical



dans lequel A, R¹, R², R³ et R⁴ sont tels que définis dans la revendication 1, caractérisé par la mise en réaction d'un réactif de formule Het-W¹ (VII) ou Het-X-H (VIII) avec une pipéridine de formule


HX-Alk-D (I-b-2-a) ou W²-Alk-D (IX), respectivement, W¹ et W² étant l'un et l'autre des groupes partants réactifs, dans un solvant inerte à l'égard de la réaction, pour l'obtention d'un composé de formule Het-X-Alk-D (I-b-2-b).

3. Procédé pour la préparation d'un composé de formule NC-CH₂-CH₂-D (I-c), dans laquelle D représente le radical




dans lequel A, R¹, R², R³ et R⁴ ont les mêmes significations que dans la revendication 1, caractérisé par l'alkylation d'une pipéridine de formule H-D (II) avec CH₂=CH-CN (XV) dans un solvant inerte à l'égard de la réaction, pour l'obtention d'un composé de formule NC-CH₂-CH₂-D (I-c); et éventuellement la réduction dudit composé en l'amine correspondante, dans un milieu contenant de l'hydrogène, en présence d'un catalyseur.

4. Procédé pour la préparation d'un composé




d'une forme N-oxyde, d'un sel d'addition thérapeutiquement actif et non toxique ou d'une forme stéréochimiquement isomère de celui-ci, dans lequel A, R¹, R², R³ et R⁴ sont tels que définis dans la revendication 1


caractérisé par la mise en réaction d'une pipéridinamine de formule



dans laquelle P¹ représente un groupe protecteur et R³ et R⁴ sont tels que définis dans la revendication 1, avec un acide carboxylique de formule



ou un dérivé fonctionnel de celui-ci, et ensuite l'élimination du groupe protecteur P¹ dans le produit intermédiaire



25

ainsi obtenu, selon des modes opératoires connus dans la technique, dans un solvant inerte à l'égard de la réaction et, si on le désire, la conversion d'un composé de formule (I) en un sel thérapeutiquement actif et non toxique, par traitement par un acide approprié, ou, inversement, la conversion d'une forme sel en une forme base libre à l'aide d'une solution alcaline; et/ou la préparation des formes N-oxyde et des formes stéréochimiquement isomères de ce composé.

30

35

40

45

50

55